

BETH C. DRAIN, CA CSR NO. 7152

BEFORE THE
APPLICATION REVIEW SUBCOMMITTEE
TO THE
CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE
ORGANIZED PURSUANT TO THE
CALIFORNIA STEM CELL RESEARCH AND CURES ACT
REGULAR MEETING

LOCATION: VIA ZOOM

DATE: JULY 20, 2021
10 A.M.

REPORTER: BETH C. DRAIN, CA CSR
CSR. NO. 7152

FILE NO.: 2021-17

BETH C. DRAIN, CA CSR NO. 7152

I N D E X

ITEM DESCRIPTION	PAGE NO.
OPEN SESSION	
1. CALL TO ORDER	3
2. ROLL CALL	3
ACTION ITEMS	
3. CONSIDERATION OF APPLICATIONS SUBMITTED IN RESPONSE TO PROGRAM ANNOUNCEMENT: BRIDGES EDUC 2.	5
4. CONSIDERATION OF APPLICATIONS SUBMITTED IN RESPONSE TO CLINICAL TRIAL STAGE PROJECTS PROGRAM ANNOUNCEMENT (CLIN 1,2 OR 3).	39
CLOSED SESSION	
NONE	
5. DISCUSSION OF CONFIDENTIAL INTELLECTUAL PROPERTY OR WORK PRODUCT, PREPUBLICATION DATA, FINANCIAL INFORMATION, CONFIDENTIAL SCIENTIFIC RESEARCH OR DATA, AND OTHER PROPRIETARY INFORMATION RELATING TO APPLICATIONS SUBMITTED IN RESPONSE TO AGENDA ITEMS 3 AND 4 ABOVE. (HEALTH & SAFETY CODE 125290.30(F) (3) (B) AND (C)).	
DISCUSSION ITEMS	
6. PUBLIC COMMENT.	NONE
7. ADJOURNMENT.	55

BETH C. DRAIN, CA CSR NO. 7152

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

JULY 20, 2021; 10 A.M.

CHAIRMAN THOMAS: WELL, THANK YOU, MARIA.
AND WELCOME, EVERYBODY, TO THE JULY 2021 MEETING OF
THE ICOC AND APPLICATION REVIEW SUBCOMMITTEE.
MARIA, WILL YOU PLEASE CALL THE ROLL.

MS. BONNEVILLE: SURE. I'M GOING TO MAKE
SURE THAT WE'VE STARTED THE RECORDING OF THE
MEETING. WE HAVE. GREAT.

DAN BERNAL. DAN, I CAN'T HEAR YOU.
LEONDR A CLARK-HARVEY. ANNE-MARIE DULIEGE.

DR. DULIEGE: YES.

MS. BONNEVILLE: YSABEL DURON.

MS. DURON: HERE.

MS. BONNEVILLE: MARK FISCHER-COLBRIE.

DR. FISCHER-COLBRIE: HERE.

MS. BONNEVILLE: FRED FISHER. ELENA
FLOWERS. DAVID HIGGINS.

DR. HIGGINS: HERE.

MS. BONNEVILLE: STEVE JUELSGAARD.

MR. JUELSGAARD: HERE.

MS. BONNEVILLE: DAVE MARTIN. CHRISTINE
MIASKOWSKI.

DR. MIASKOWSKI: HERE.

MS. BONNEVILLE: LAUREN MILLER-ROGEN.

BETH C. DRAIN, CA CSR NO. 7152

1 ADRIANA PADILLA.
2 DR. PADILLA: HERE.
3 MS. BONNEVILLE: JOE PANETTA.
4 MR. PANETTA: HERE.
5 MS. BONNEVILLE: AL ROWLETT.
6 MR. ROWLETT: HERE.
7 MS. BONNEVILLE: OS STEWARD.
8 DR. STEWARD: HERE.
9 MS. BONNEVILLE: JONATHAN THOMAS.
10 CHAIRMAN THOMAS: HERE.
11 MS. BONNEVILLE: ART TORRES.
12 MR. TORRES: HERE.
13 MS. BONNEVILLE: AND I BELIEVE KAROL
14 WATSON IS JUST JOINING NOW. SO I WILL CALL HER NAME
15 IN A MOMENT.
16 DR. MELMED: YOU NEVER CALLED MY NAME. IS
17 THERE A REASON?
18 MS. BONNEVILLE: YOU ARE -- YES. NO,
19 THAT'S FINE. SHLOMO MELMED.
20 AND LARRY GOLDSTEIN, I THINK YOU JOINED AS
21 WELL.
22 MR. TORRES: HE WAS ON EARLIER.
23 DR. GOLDSTEIN: I'M HERE. SORRY. I'M
24 MUTED.
25 MS. BONNEVILLE: YES. THANK YOU. GO

BETH C. DRAIN, CA CSR NO. 7152

1 AHEAD, J.T.

2 CHAIRMAN THOMAS: THANK YOU, MARIA. OKAY.
3 WE'LL GO ON TO THE ACTION ITEMS. THERE ARE TWO
4 ACTION ITEMS HERE, AND THIS IS THE APPLICATION
5 REVIEW SUBCOMMITTEE PORTION OF THE MEETING. I WILL
6 BE LEADING THE FIRST AND OS WILL BE LEADING THE
7 SECOND.

8 FIRST IS CONSIDERATION OF APPLICATIONS
9 SUBMITTED IN RESPONSE TO PROGRAM ANNOUNCEMENT
10 BRIDGES EDUCATION² RFA. AND WE'LL HAVE A
11 PRESENTATION BY DR. SAMBRANO.

12 DR. SAMBRANO: OKAY. GOOD MORNING,
13 EVERYBODY. THANK YOU. LET ME JUST PUT UP THE
14 PRESENTATION. ALL RIGHT.

15 SO I'M GOING TO GIVE YOU AN OVERVIEW OF
16 THE RECOMMENDATIONS FROM THE GRANTS WORKING GROUP
17 REGARDING THE CIRM BRIDGES TRAINING PROGRAM AND A
18 LITTLE BACKGROUND ON THE BRIDGES PROGRAM ITSELF JUST
19 AS A REMINDER OF WHAT THIS IS ABOUT.

20 SO IN OUR -- AMONG OUR PILLARS IN OUR
21 EDUCATION PILLAR, WE HAVE SEVERAL TYPES OF PROGRAMS
22 FOCUSED ON TRAINING THAT SPAN FROM HIGH SCHOOL TO
23 POSTDOCTORAL AND CLINICAL FELLOWS. THE BRIDGES
24 PROGRAM IN PARTICULAR IS FOCUSED ON TRAINING
25 UNDERGRADUATE AND MASTER'S LEVEL TRAINEES. AND THIS

BETH C. DRAIN, CA CSR NO. 7152

1 AWARD WAS FIRST IMPLEMENTED IN 2009. SO IT'S GONE
2 ON FOR ABOUT 12 YEARS, AND WE'VE HAD 16 DIFFERENT
3 GRANT AWARDS THAT HAVE BEEN ISSUED FOR THIS PROGRAM
4 AND HAS TRAINED OVER 1600 INDIVIDUALS.

5 THE OBJECTIVE OF THE BRIDGES TRAINING
6 PROGRAM IS TO PREPARE CALIFORNIA'S UNDERGRADUATE AND
7 MASTER'S GRADUATE STUDENTS FOR PRODUCTIVE CAREERS IN
8 STEM CELL RESEARCH AND THERAPY DEVELOPMENT. AND
9 WE'VE, OF COURSE, BROADENED THAT TO REGENERATIVE
10 MEDICINE AND GENE THERAPY. AND THE WAY THESE
11 PROGRAMS ARE STRUCTURED, THEY'RE INTEGRATED INTO
12 EXISTING BACHELOR'S, MASTER'S, OR CERTIFICATE
13 PROGRAMS AT THE HOME INSTITUTION THROUGHOUT THE
14 STATE OF CALIFORNIA. AND THE PROGRAMS PROVIDE
15 OPPORTUNITIES TO STUDENTS IN ORDER TO BRING THEM TO
16 RESEARCH THAT MIGHT NOT BE AVAILABLE AT THEIR OWN
17 INSTITUTION. SO THEY PARTICIPATE IN INTERNSHIPS AT
18 HOST INSTITUTIONS THAT ARE CONDUCTING CUTTING-EDGE
19 RESEARCH.

20 SO SOME OF THE FEATURES OF THE BRIDGES
21 TRAINING PROGRAM INCLUDE COURSEWORK THAT'S PROVIDED
22 TO THE STUDENTS INCLUDING A LAB TECHNIQUES COURSE
23 WHERE THEY MAY LEARN ADVANCED CELL CULTURE
24 TECHNIQUES, EVEN HOW TO CULTURE HUMAN EMBRYONIC STEM
25 CELLS AND OTHER ADVANCED TECHNIQUES. THEY HAVE

BETH C. DRAIN, CA CSR NO. 7152

1 PATIENT ENGAGEMENT AND COMMUNITY OUTREACH ACTIVITIES
2 WHICH ALLOWS THEM TO ENGAGE WITH AND GET TO KNOW
3 PATIENTS AND PATIENT ADVOCATES AS WELL AS ALSO
4 ENGAGE IN COMMUNITY OUTREACH WHERE THEY WILL MAKE
5 PRESENTATIONS TO HIGH SCHOOLS OR ELEMENTARY SCHOOLS
6 OR PARTICIPATE IN FAIRS TO TEACH OTHERS ABOUT
7 REGENERATIVE MEDICINE AND STEM CELL RESEARCH.

8 OF COURSE, THE MAIN COMPONENT IS THE PAID
9 RESEARCH INTERNSHIPS AT THE HOST INSTITUTIONS WHERE
10 THEY'RE CONDUCTING RESEARCH, AND THOSE VARY IN
11 OVERALL TIME FROM ABOUT EIGHT MONTHS TO A YEAR.

12 AND THEN, FINALLY, THERE'S THE ANNUAL
13 BRIDGES CONFERENCE WHICH IS SUPPORTED SEPARATELY,
14 BUT ONE THAT WE PROVIDE FUNDING FOR IN ORDER TO
15 BRING ALL OF THE STUDENTS TOGETHER EACH YEAR WHERE
16 THEY PRESENT THE OUTCOMES OF THEIR RESEARCH
17 INTERNSHIP AND POSTER PRESENTATIONS, AND THEY HAVE
18 THE OPPORTUNITY TO HEAR PRESENTATIONS FROM OTHER
19 SCIENTISTS AS WELL.

20 AND SO THIS IS JUST SOME OF THE OUTCOME
21 AND IMPACT DATA THAT WE'VE COLLECTED. SO THIS IS A
22 LITTLE OLD. IT'S NOT THE MOST RECENT. THIS IS UP
23 THROUGH 2020. AND AT THE TIME WE HAD ABOUT 1500
24 ALUMNI IN THOSE FIRST 11 YEARS, AND WE DID A SURVEY,
25 AS WE OCCASIONALLY DO, OF INTERNS OF JUST HOW

BETH C. DRAIN, CA CSR NO. 7152

1 THEY'RE DOING. AND WE LEARNED THAT ABOUT 48 PERCENT
2 OF THOSE SURVEY RESPONDERS ARE FIRST GENERATION
3 COLLEGE STUDENTS, THAT GREATER THAN 60 PERCENT
4 BECOME EMPLOYED IN R & D POSITIONS. SO 53 PERCENT
5 ARE IN ACADEMIC LABS, 47 PERCENT IN BIOTECH OR
6 PHARMA, ABOUT 35 PERCENT ARE IN PH.D., PROFESSIONAL,
7 OR OTHER GRADUATE PROGRAMS INCLUDING MEDICAL SCHOOL.
8 MANY OF THEM WILL DECIDE TO GO INTO HIGHER
9 EDUCATION. AND OVERALL THE ACTIVITIES OF THESE
10 STUDENTS HAS CONTRIBUTED TO 261 PUBLICATIONS IN
11 SCIENTIFIC JOURNALS THROUGH THE PROGRAM.

12 SO THOSE THAT MAY APPLY FOR A BRIDGES
13 PROGRAM ARE CALIFORNIA UNIVERSITIES OR COLLEGES THAT
14 DON'T HAVE A MAJOR STEM CELL RESEARCH PROGRAM. SO
15 THE IDEA IS TO FOCUS THIS PROGRAM LARGELY ON THE
16 CALIFORNIA STATE UNIVERSITIES, SO THE PRIVATE
17 UNIVERSITIES AND COMMUNITY COLLEGES, AND TO BRING
18 OPPORTUNITIES INTO THOSE INSTITUTIONS THAT WILL
19 ALLOW THOSE STUDENTS TO BE EXPOSED TO CUTTING-EDGE
20 RESEARCH.

21 SO FOR THIS OPPORTUNITY, THE ICOC HAS
22 APPROVED UP TO \$65 MILLION TO SUPPORT UP TO 18
23 AWARDS WITH EACH AWARD SUPPORTING UP TO TEN TRAINEES
24 PER YEAR, AND EACH AWARD WOULD PROVIDE UP TO 3.6
25 MILLION FOR A FIVE-YEAR PERIOD.

BETH C. DRAIN, CA CSR NO. 7152

1 SO THAT WAS THE CONCEPT THAT WAS APPROVED
2 PREVIOUSLY.

3 THERE ARE SOME AWARD PRIORITIES THAT ARE
4 HIGHLIGHTED IN PROP 14, AND I JUST WANT TO MENTION
5 THEM, AND I'LL ALLUDE TO THESE A LITTLE BIT LATER
6 WHEN I SHOW YOU THE OUTCOMES.

7 APPLICATIONS THAT OFFER MATCHING FUNDS ARE
8 VERIFIED IN-KIND SUPPORT AS WELL AS APPLICATIONS
9 THAT ENHANCE THE GEOGRAPHIC DISTRIBUTION OF THE
10 TRAINING AND SOCIOECONOMIC DIVERSITY ARE HIGHLIGHTED
11 AS ELEMENTS THAT SHOULD BE PRIORITIZED IN THESE
12 PROGRAMS.

13 THE SCORING SYSTEM THAT WAS USED BY THE
14 GRANTS WORKING GROUP TO ASSESS THESE WAS A RANGE OF
15 ONE TO A HUNDRED WITH SCORES OF 85 TO A HUNDRED
16 BEING A RECOMMENDATION TO FUND IF FUNDS ARE
17 AVAILABLE. AND THE REVIEW CRITERIA THAT WERE
18 UTILIZED IN SCORING THE APPLICATIONS ARE BASED ON
19 THE FOLLOWING FOUR QUESTIONS: DOES THE PROPOSED
20 PROGRAM HAVE THE NECESSARY SIGNIFICANCE AND
21 POTENTIAL FOR IMPACT? IS THE TRAINING PROGRAM
22 WELL-PLANNED AND DESIGNED? IS IT PRACTICAL AND
23 ACHIEVABLE? AND DO THEY HAVE A TRACK RECORD AND
24 OUTCOMES OF PRIOR TRAINING PROGRAMS DEMONSTRATING
25 SUCCESS?

BETH C. DRAIN, CA CSR NO. 7152

1 AND SO THIS IS JUST A TABLE THAT
2 SUMMARIZES THE OVERALL RECOMMENDATIONS. THERE WERE
3 15 APPLICATIONS THAT WERE SUBMITTED AND REVIEWED.
4 FOURTEEN OF THEM WERE RECOMMENDED FOR FUNDING WITH A
5 TOTAL APPLICANT REQUEST FOR THOSE 14 OF ABOUT \$48
6 MILLION. FUNDS AVAILABLE, AGAIN, ARE 65 MILLION, SO
7 WELL WITHIN THE AMOUNT THAT IS AVAILABLE.

8 THERE WAS ONE APPLICATION THAT WAS NOT
9 RECOMMENDED FOR FUNDING, AND THE CIRM TEAM'S
10 RECOMMENDATION IS TO FUND ALL THOSE THAT ARE
11 RECOMMENDED, SO THE 14 WITH THE SCORE OF 85 OR
12 GREATER.

13 SO LET'S SEE. THAT IS IT FOR THAT. LET
14 ME JUST SHARE -- HOLD ON A SECOND. I'M GOING TO
15 SHOW YOU THE SPREADSHEET THAT SHOWS THE LIST OF
16 PROGRAMS. AND I WANT TO JUST ORIENT YOU JUST A
17 LITTLE BIT ON THIS. SO THIS IS PART OF THE COVER
18 SHEET THAT WAS PROVIDED WITH THE SUMMARIES. BUT
19 HERE I'M ALSO SHOWING A COUPLE OF OTHER THINGS. THE
20 PROPOSED MATCH OR IN-KIND SUPPORT PROVIDED BY EACH
21 OF THESE APPLICANTS I'M SHOWING YOU HERE. AS YOU
22 CAN SEE, ALMOST ALL OF THEM PROVIDED SOME LEVEL OF
23 MATCH OR IN-KIND SUPPORT. THIS ISN'T NECESSARILY
24 CASH OR FUNDS. IN MANY CASES THIS IS A COMBINATION
25 OF EITHER RELIEF TIME FOR THEIR FACULTY, EQUIPMENT

BETH C. DRAIN, CA CSR NO. 7152

1 THAT IS PROVIDED, FUNDS TO SUPPORT AN ELEVENTH
2 TRAINEE IN THE PROGRAM, THINGS SUCH AS THAT. I'M
3 ALSO SHOWING THE CALIFORNIA REGION FOR EACH OF THESE
4 APPLICATIONS JUST TO ALSO SHOW YOU THE DIVERSITY OF
5 THE REGIONS, THE GEOGRAPHIC DISTRIBUTION THAT EXISTS
6 AMONG ALL OF THESE DIFFERENT PROGRAMS SO THAT YOU
7 CAN SEE THAT AS WELL.

8 SO WITH THAT, I'LL TURN IT BACK TO
9 CHAIRMAN THOMAS.

10 CHAIRMAN THOMAS: THANK YOU, DR. SAMBRANO.

11 FIRST ORDER OF BUSINESS HERE IS TO DO WE
12 HAVE ANY MOTIONS TO MOVE THE TIER II PROPOSAL UP
13 INTO TIER I?

14 DR. DULIEGE: J.T., I HAVE A QUESTION, NOT
15 A MOTION. IS THAT THE RIGHT TIME OR NOT?

16 CHAIRMAN THOMAS: WELL, I THINK IF
17 SOMEBODY WANTS TO MAKE A MOTION TO MOVE THAT UP, WE
18 CAN HAVE THE QUESTION THEN. WHY DON'T YOU JUST GO
19 AHEAD, ANNE-MARIE.

20 DR. DULIEGE: GIL, THANK YOU VERY MUCH FOR
21 AN EXCELLENT PRESENTATION AS WELL. WE DID READ THE
22 E-MAIL OR THE LETTER FROM -- AN APPEAL LETTER FROM,
23 I BELIEVE, THAT PARTICULAR SITE. CAN YOU MAKE ANY
24 COMMENT ABOUT WHY THIS SITE STOOD OUT AS NOT
25 RECOMMENDED FOR FUNDING, AND THE COMMENTS

BETH C. DRAIN, CA CSR NO. 7152

1 PARTICULARLY ON THEIR APPEAL LETTER? THANK YOU.

2 DR. SAMBRANO: SURE. I MEAN I CAN COMMENT
3 TO THE EXTENT POSSIBLE. SO THE APPLICANT IS, AS YOU
4 NOTED, THE ONE THAT WAS NOT RECOMMENDED FOR FUNDING.
5 AND THERE WERE SEVERAL REASONS WHY THIS APPLICATION
6 STOOD OUT. AND PART OF IT IS THE PROGRAM HAD A
7 PROPOSAL TO CREATE OPPORTUNITIES FOR TRAINEES, BUT
8 THEY WEREN'T FULLY ARTICULATED OR FLESHED OUT.

9 AND SO I THINK RELATIVE TO THE OTHER
10 PROGRAMS, IT'S THE ONE THAT SEEMED TO HAVE LESS
11 DETAIL AND FORMAL STRUCTURE TO IT.

12 I THINK ONE OF THE THINGS THAT STOOD OUT
13 WAS THE SELF-PLACEMENT OF THE STUDENTS INTO THE
14 INTERNSHIPS. ALTHOUGH, AS NOTED BY THE APPLICANT,
15 IT ISN'T FULLY SELF-PLACEMENT OF THE TRAINEES, BUT
16 IT IS UNUSUAL IN THAT A LOT OF THE ACTIVITY IS LEFT
17 TO THE TRAINEE TO FIND THE LABORATORY WHERE THEY'RE
18 GOING TO DO THE INTERNSHIP. AND THERE WAS, I THINK,
19 HESITATION AND/OR FEAR FROM REVIEWERS THAT THIS
20 MIGHT NOT BE THE BEST APPROACH TO PLACING STUDENTS
21 IN THOSE INTERNSHIPS. SO I THINK IT WAS A
22 COMBINATION OF THOSE THINGS THAT GAVE REVIEWERS
23 PAUSE IN THE PROGRAM.

24 THE OTHER THING THAT I WILL NOTE IS THAT
25 ALL THE ONES THAT ARE RECOMMENDED HAVE HAD A RECENT

BETH C. DRAIN, CA CSR NO. 7152

1 BRIDGES TRAINING PROGRAM. IN OTHER WORDS, THEY'RE
2 BASICALLY RENEWING THE PROGRAM THAT IS CURRENTLY
3 ACTIVE. THIS ONE THAT WAS NOT RECOMMENDED DID HAVE
4 ONE PREVIOUSLY WHEN WE FIRST STARTED THE BRIDGES
5 PROGRAM. THEY COMPETED IN A RENEWAL FOR IT, DID NOT
6 GET IT, AND SO THEY HAVEN'T BEEN FUNDING THAT
7 PROGRAM BECAUSE OF THAT. SO THEY HAVE NOT BEEN UP
8 TO SPEED IN TERMS OF HAVING AN ACTIVE PROGRAM IF
9 THAT MAKES SENSE.

10 CHAIRMAN THOMAS: OKAY. FOR THE SAKE OF
11 ARGUMENT HERE, I'M GOING TO, FOR A VARIETY OF
12 REASONS, MOVE THAT WE MOVE THIS APPLICATION UP TO
13 TIER I, WHICH I WILL EXPLAIN IF WE HAVE A SECOND TO
14 THAT EFFECT.

15 MS. DURON: I SECOND.

16 CHAIRMAN THOMAS: THANK YOU, YSABEL. SO
17 I'LL OPEN THE COMMENTS HERE.

18 IN READING THE DIRECTOR'S APPEAL LETTER,
19 TO ME I FOUND IT QUITE PERSUASIVE. IT
20 ACKNOWLEDGES -- IT ANSWERS A NUMBER OF THE ISSUES
21 THAT DR. SAMBRANO HAS ARTICULATED. DID NOTE THAT
22 THE SELF-SELECTION PROCESS ACTUALLY WORKED, IN HER
23 OPINION, WELL IN THE PREVIOUS ITERATION. BUT ONE OF
24 THE THINGS THAT WAS MOST NOTABLE ABOUT THIS LETTER
25 WAS IT ACKNOWLEDGED SOME VERY HELPFUL SUGGESTIONS

BETH C. DRAIN, CA CSR NO. 7152

1 FROM THE GWG THAT WOULD BE INCORPORATED TO MAKE THIS
2 PROGRAM AN EVEN BETTER PROGRAM THAN IT WAS TO BEGIN
3 WITH, WHICH I FOUND TO BE A REFRESHING APPROACH
4 SINCE A LOT OF TIMES AN APPEAL LETTER, IT'S ALWAYS
5 ABOUT HOW THE GWG HAS IT WRONG OR WHATEVER. THERE
6 WAS A REAL EFFORT HERE TO TAKE TO HEART WHAT WAS
7 SAID.

8 AS YOU CAN SEE ON THE SCORING, THIS GOT AN
9 80. THIS ISN'T SOMETHING THAT WAS DOWN IN THE 50
10 RANGE. IT WAS QUITE CLOSE TO THE RECOMMENDED FOR
11 FUNDING LEVEL. I THINK THAT HAVING BERKELEY
12 REPRESENTED IN THE PROGRAM WOULD BE A VERY POSITIVE
13 THING, OBVIOUSLY BEING A VERY IMPORTANT CENTER OF
14 LEARNING.

15 AND THEN IF YOU GO TO THE SECOND LETTER
16 WRITTEN BY ONE OF THE PREVIOUS STUDENTS AND YOU READ
17 HIS STORY AND HIS ARTICULATION OF WHAT'S HAPPENED TO
18 OTHERS FROM HIS PARTICULAR CLASS, IT'S EXACTLY WHAT
19 YOU'D WANT TO SEE FROM THIS TERRIFIC PROGRAM. AND I
20 DO WANT TO GIVE A SHOUT-OUT HERE TO ART AS BEING THE
21 ONE WHO BROUGHT THIS TO CIRM, THE IDEA, BACK MANY
22 YEARS AGO. BUT HIS STORY IS PRECISELY WHAT YOU WANT
23 TO SEE COMING OUT OF THIS. AND SO FOR ALL OF THESE
24 REASONS, I FIND THE APPEALS PERSUASIVE AND I WOULD
25 SUPPORT MOVING THIS UP TO TIER I.

BETH C. DRAIN, CA CSR NO. 7152

1 ARE THERE OTHER COMMENTS FROM MEMBERS OF
2 THE BOARD?

3 MS. DURON: J.T., YSABEL HERE.

4 MS. BONNEVILLE: I SEE AL HAS HIS HAND
5 RAISED. SORRY, YSABEL.

6 MS. DURON: THAT'S OKAY.

7 CHAIRMAN THOMAS: AL FIRST, THEN YSABEL.
8 AL.

9 MS. DURON: I SHOULD BE A GOOD STUDENT.

10 MR. ROWLETT: THANKS, YSABEL.

11 MS. DURON: NOT A PROBLEM.

12 MR. ROWLETT: SO AS A PARTICIPANT IN THIS
13 PARTICULAR APPLICATION, WITHOUT TALKING ABOUT THE
14 SPECIFICS ASSOCIATED WITH MY SCORE, I WANT TO MAKE
15 SURE THAT MEMBERS OF THE BOARD APPRECIATE THAT, ONE,
16 THIS BEING A COMMUNITY COLLEGE WAS NOT A DETERRENT
17 FROM MY PERSPECTIVE IN THE APPLICATION WHATSOEVER.
18 AND, IN FACT, AS I LOOKED AT IT INITIALLY, I WAS
19 MORE INCLINED BECAUSE IT WAS A COMMUNITY COLLEGE.

20 SECOND, IF YOU LOOK AT THE RANGE OF SCORES
21 FOR THE DAY, THEY WERE OVERWHELMINGLY POSITIVE. IT
22 WOULD HAVE PROBABLY BEEN A DIFFERENT OUTCOME,
23 ALTHOUGH I CAN'T PREDICT WHAT WOULD HAPPEN WITH
24 CERTAINTY, HAD THEY INCLUDED SOME OF THE KEY POINTS
25 THAT WERE INCLUDED IN THE LETTER, THE LETTERS THAT

BETH C. DRAIN, CA CSR NO. 7152

1 WERE SUBMITTED. AND THAT'S -- THAT'S THE REALITY.
2 AND THAT'S PART OF THE REASON WHY THIS WAS SCORED
3 THE WAY IT WAS.

4 I PROBABLY IN ALL LIKELIHOOD WILL VOTE TO
5 SUPPORT J.T.'S MOTION OF MOVING IT UP, BUT, AGAIN,
6 WANTED TO MAKE SURE THAT PEOPLE APPRECIATED THAT.

7 CHAIRMAN THOMAS: THANK YOU. LET'S HAVE
8 YSABEL, THEN ANNE-MARIE, THEN FRED, THEN OS.

9 MS. DURON: THANK YOU, J.T. AND I
10 APPRECIATE AL REFERRING TO THE LETTER THAT WAS
11 WRITTEN VIS-A-VIS THE GRANT PROPOSAL. I WAS
12 THINKING THAT, LIKE ME, WE PROBABLY NEED A BETTER
13 GRANT WRITER. BUT I REALLY APPRECIATE, IN FACT,
14 THAT THIS IS A CITY COLLEGE, THAT THREE-QUARTERS OF
15 ITS STUDENTS ARE PEOPLE OF COLOR, THAT THIS
16 PRESIDENT AND THIS BIOLOGY ADVOCATE -- EXCUSE ME --
17 THE PROGRAM DIRECTOR FROM BIOTECHNOLOGY ARE
18 PASSIONATE ABOUT MAKING SURE THAT THEIR STUDENTS
19 HAVE THESE OPPORTUNITIES EVEN THOUGH THEY DON'T GO
20 TO SOME OF THE HIGH NAMED COLLEGES AND WELL-FUNDED
21 AND/OR WELL-UNDERSTOOD COLLEGES.

22 I JUST -- I'M JUST REALLY THINKING THAT
23 THIS IS EXACTLY WHERE WE NEED TO START CREATING
24 THOSE PATHWAYS TO RESEARCH SUCCESS BY ALLOWING,
25 ENCOURAGING, EMBRACING THESE KINDS OF CITY COLLEGE

BETH C. DRAIN, CA CSR NO. 7152

1 OPPORTUNITIES FOR KIDS WHO MIGHT NORMALLY NOT FEEL
2 SECURE, NOT GET ENTRY INTO THE MAJOR COLLEGES TO
3 TEST THEIR UNDERSTANDING, LOVE, AND ABILITY TO
4 MANAGE SCIENCE. I DIDN'T EVEN LIKE CUTTING UP
5 FROGS. WHO WAS TO SAY I WAS GOING TO END UP ON THE
6 OTHER SIDE OF THIS TRYING TO FIGURE OUT STEM CELLS?

7 SO I JUST THINK THAT I WOULD GIVE THEM
8 EVERY OPPORTUNITY TO BRING THEIR PROGRAM UP TO
9 SNUFF, WHICH THEY WANT TO DO. AND I WOULD ALSO
10 RECOMMEND THAT PERHAPS WE GIVE THEM A HELPING HAND
11 BY PERHAPS CONNECTING THEM SO THEY CAN LEVERAGE
12 THEIR LEARNING WITH SOME OF THE OTHERS WHO MIGHT
13 MENTOR THEM AND HELP THEM UNDERSTAND HOW TO
14 (INAUDIBLE). THEY ARE TALKING ABOUT DEVELOPING AND
15 LEARNING BEST PRACTICES, AND I THINK THAT THIS IS
16 TRULY A LEARNING CURVE FOR THEM AS WELL.

17 I'M SO GLAD YOU MOVED THIS UP, J.T. I
18 TRULY WANT TO SEE THIS GROUP SUCCEED.

19 CHAIRMAN THOMAS: THANK YOU, YSABEL.

20 ANNE-MARIE.

21 DR. DULIEGE: YEAH. BRIEFLY, YSABEL, I
22 COMPLETELY AGREE WITH ALL YOUR COMMENTS. QUESTION
23 TO GIL, J.T., AND OTHERS. SHOULD WE BE INFLUENCED
24 IN OUR VOTE BY THE FACT THAT THIS IS A SOCIOECONOMIC
25 UNDERPRIVILEGED AREA, THE BERKELEY/OAKLAND, AND THAT

BETH C. DRAIN, CA CSR NO. 7152

1 WE SHOULD FACILITATE -- AS A PLEDGE TO DIVERSITY, WE
2 SHOULD FACILITATE ACCESS TO TRAINING PARTICULARLY IN
3 THESE UNDERPRIVILEGED AREAS IN CALIFORNIA? SHOULD
4 THAT INFLUENCE OUR JUDGMENT?

5 CHAIRMAN THOMAS: YES. YES, ABSOLUTELY IN
6 MY OPINION.

7 MS. DURON: YES.

8 CHAIRMAN THOMAS: GIL, DO YOU WANT TO
9 COMMENT ON THAT?

10 DR. SAMBRANO: NO, I REALLY DON'T HAVE ANY
11 OTHER COMMENT. AS I MENTIONED EARLIER, THE
12 SOCIOECONOMIC DIVERSITY IS AN ELEMENT THAT SHOULD BE
13 CONSIDERED, WHICH IS IN PART WHY WE PUT THIS
14 CALIFORNIA REGION ELEMENT IN THERE AS WELL.

15 CHAIRMAN THOMAS: OKAY. THANK YOU. FRED.

16 DR. FISHER: NEW TO THIS WHOLE THING, AND
17 MY EXPERIENCE THUS FAR HAS BEEN ABOUT CIRM ADVANCING
18 GREAT SCIENCE, BUT NOW I HAVE COME TO UNDERSTAND,
19 AFTER REVIEWING ALL THE MATERIALS, THAT CIRM IS ALSO
20 A CAPACITY BUILDER. AND IT'S DONE THAT IN DIFFERENT
21 WAYS. IT'S PROVIDED ENORMOUS FUNDING TO BUILD THE
22 CAPACITY, BUILDING INFRASTRUCTURE AT MAJOR
23 INSTITUTIONS, WHICH HAS SHOWN GREAT RESULTS. AND I
24 WAS MORE MOVED BY THE LETTERS FROM THE STUDENTS THAT
25 HAVE BEEN THROUGH THE PROGRAM AS EVIDENCE OF

BETH C. DRAIN, CA CSR NO. 7152

1 CAPACITY BUILDING, THAT THE OUTCOMES OF THOSE
2 STUDENTS REALLY SEEMED TO BE IN LINE WITH WHAT
3 CIRM'S OBJECTIVES ARE THROUGH THIS FUNDING CHANNEL.
4 AND BUILDING CAPACITY BY INCUBATING THE INTEREST OF
5 POTENTIAL GREAT SCIENTISTS EARLY IN THEIR ACADEMIC
6 LIFE, IF THAT'S WHAT WE ARE TRYING TO ACHIEVE, THEN
7 THOSE LETTERS SEEM TO SUGGEST CIRM HAS BEEN
8 ACHIEVING THAT THROUGH THIS INSTITUTION. AND IF
9 THERE ARE THINGS THAT WE CAN DO TO HELP THEM
10 CONTINUE IN THAT WAY, THEN IT SEEMS LIKE A WORTHY
11 INVESTMENT.

12 CHAIRMAN THOMAS: THANK YOU, FRED. VERY
13 WELL SAID. I HUNDRED PERCENT AGREE WITH YOU.

14 OS.

15 DR. STEWARD: YEAH, THANKS. JUST TO PICK
16 UP ACTUALLY ON THE VERY LAST THING THAT FRED SAID, I
17 AM GOING TO VOTE IN FAVOR OF THIS, BUT I WOULD LIKE
18 TO SUGGEST A FRIENDLY AMENDMENT, IF I MAY. AND LET
19 ME EXPLAIN THE PURPOSE OF THAT.

20 I THINK THE -- WELL, FIRST OF ALL, THE
21 GRANTS WORKING GROUP ALWAYS READS EVERY GRANT IN THE
22 GREATEST DETAIL AND TAKES INCREDIBLE TIME LOOKING AT
23 THE STRENGTHS AND WEAKNESSES. AND THEY DID FIND
24 WEAKNESSES HERE, WHICH THEY POINTED OUT AND THAT GIL
25 HAS ALREADY TALKED ABOUT. AND THAT MAIN WEAKNESS

BETH C. DRAIN, CA CSR NO. 7152

1 WAS THE -- LETTING THINGS HAPPEN IN TERMS OF THE
2 .JTRAINEE FINDING AN ADVISOR IN A FAIRLY
3 UNCONTROLLED WAY.

4 I THINK THAT ACTUALLY IS AN EVEN MORE
5 IMPORTANT WEAKNESS FOR EXACTLY THE REASONS THAT
6 YSABEL AND OTHERS HAVE TALKED ABOUT HERE BECAUSE
7 THIS IS NOT A TRAINING ENVIRONMENT WHERE THERE'S A
8 STRUCTURED FORM. AND SO I THINK THAT THERE IS A
9 CHANCE OF STUDENTS QUICKLY GETTING LOST AND LOSING
10 THEIR WAY IN ENGAGING.

11 NOW, I THINK THERE'S A VERY EASY SOLUTION
12 HERE, AND THAT'S WHAT MY FRIENDLY AMENDMENT IS. AND
13 THAT IS TO RECOMMEND APPROVAL WITH THE PROVISIO OR
14 CAVEAT OR WHATEVER THAT THE PROGRAM PROVIDE AN
15 INTERIM REPORT AT THE END OF THE YEAR ON STUDENT
16 SUCCESS. THE INDIVIDUAL LETTERS WERE VERY
17 IMPRESSIVE, BUT WE DON'T REALLY HAVE A FEELING FOR
18 HOW MANY STUDENTS MIGHT HAVE BEEN LOST IN PREVIOUS
19 PROGRAMS. I'D PREFER TO SEE ACTUAL DATA RATHER THAN
20 ATTESTATIONS. I THINK THAT'S A WORD.

21 SO MY FRIENDLY AMENDMENT WOULD READ
22 SOMETHING LIKE THIS: APPROVE WITH THE PROVISIO THAT
23 THE PROGRAM DEVELOP A SUCCESSFUL MENTORING ADVISED
24 SYSTEM THAT CAN BE DOCUMENTED TO BE SUCCESSFUL BY
25 THE END OF THE FIRST YEAR, SOMETHING ALONG THOSE

BETH C. DRAIN, CA CSR NO. 7152

1 LINES. WHATEVER THE WORDS ARE, THAT'S THE GIST OF
2 WHAT I'M SUGGESTING. THANK YOU.

3 CHAIRMAN THOMAS: OKAY. THANK YOU, OS.
4 I'M FULLY AMENABLE TO THAT FRIENDLY AMENDMENT.
5 YSABEL, IS THAT OKAY WITH YOU AS THE SECONDING
6 PARTY?

7 MS. DURON: YES. I LIKE THE IDEA OF WHAT
8 HE'S TALKING ABOUT FOR THE INTERIM REPORT AND FOR
9 THEM TO STRENGTHEN SOME OF THE WEAKNESSES IN THE
10 PROGRAM. BUT WHEN I TALKED ALSO ABOUT MENTEE, I'M
11 TALKING ABOUT ACROSS THE SYSTEMS. MAYBE THEY SHOULD
12 WORK WITH SAN FRANCISCO CITY COLLEGE WHICH SEEMS TO
13 HAVE FIGURED OUT A WINNING FORMULA -- AND I THINK
14 THEY'RE ALSO FUNDED HERE OR BEING RECOMMENDED FOR
15 FUNDING. I THOUGHT I SAW THEIR NAME ON HERE -- OR
16 SOME OTHER GROUP WHERE THEY CAN ACTUALLY
17 CROSS-POLLINATE THEIR STUDENTS AND LEARN FROM EACH
18 OTHER AND LEARN BEST PRACTICES AND SO ON AND SO
19 FORTH. SO THAT MIGHT BE JUST A PROGRAM IDEA AS
20 OPPOSED TO PART OF A FRIENDLY AMENDMENT.

21 CHAIRMAN THOMAS: OKAY. ARE THERE OTHER
22 COMMENTS BY MEMBERS -- FRED.

23 DR. FISHER: SO IS THERE -- IS IT
24 APPROPRIATE FOR CIRM TO ACTUALLY PRESCRIBE THE
25 PROCESS, OR ARE WE COMFORTABLE LEAVING IT TO EACH

BETH C. DRAIN, CA CSR NO. 7152

1 INSTITUTION TO FIGURE OUT HOW BEST THEY SHOULD BE
2 STEWARDING THEIR STUDENTS? BECAUSE I THINK THE
3 ISSUE AND THE AMENDMENT THAT OS PROPOSES MAKES
4 SENSE, AND THEN YSABEL'S COMMENTS SUGGEST MAYBE
5 THERE'S A NEED FOR STANDARDIZATION IN TERMS OF HOW
6 THESE -- HOW THIS PROGRAM CHANNEL GETS EXECUTED AT
7 THE SITE LEVEL, AND THOSE BECOMING PREREQUISITES FOR
8 FUNDING AS MEETING THOSE STANDARDS OR WHAT WE'D WANT
9 TO SEE IN TERMS OF THAT.

10 CHAIRMAN THOMAS: OS?

11 DR. STEWARD: SO AS A DIRECT ANSWER TO
12 YOUR QUESTION, FRED, YES, I THINK THAT CIRM DOES
13 HAVE THE ABILITY AND AUTHORITY AND ACTUALLY
14 RESPONSIBILITY TO REQUIRE CERTAIN THINGS. WE DO FOR
15 OUR RESEARCH GRANTS THINGS THAT SOMETIMES ARE
16 UNCOMFORTABLE FOR THE INVESTIGATORS AT FIRST. AND I
17 TOTALLY APPRECIATE AND AGREE THAT THE
18 CHARACTERISTICS OF A PROGRAM REALLY DEPEND ON THE
19 SITUATIONS AT THE INSTITUTIONAL LEVEL. AND I'M NOT
20 PRESCRIBING HERE. I'M NOT SAYING THAT WE'RE GOING
21 TO DEMAND A PARTICULAR THING. I'M PROPOSING THAT WE
22 REQUIRE THEM TO SHOW THAT THEIR CHOICE OF THING
23 ACTUALLY WORKED AT THE END OF THE YEAR. THAT'S ALL.
24 AND IF IT DIDN'T, IF THEY'RE LOSING STUDENTS OR
25 STUDENTS ARE HAVING A HARD TIME, THEN I THINK THAT

BETH C. DRAIN, CA CSR NO. 7152

1 THERE NEEDS TO BE A VERY, VERY RAPID ADJUSTMENT SO
2 THAT THIS PROGRAM CAN SUCCEED BECAUSE IT REALLY, I
3 THINK, IS AN IMPORTANT PROGRAM, BUT WE DON'T WANT TO
4 HAVE THE STUDENTS GET LOST. THANK YOU.

5 CHAIRMAN THOMAS: THANK YOU, FRED, AND
6 THANK YOU, OS. ARE THERE OTHER COMMENTS FROM
7 MEMBERS OF THE BOARD?

8 MR. TORRES: YES, J.T. IT'S ART. I DON'T
9 THINK I CAN OPINE ON THE PROJECT BECAUSE I'M
10 CONFLICTED --

11 MS. BONNEVILLE: ART, YOU CANNOT COMMENT
12 ON THIS.

13 MR. TORRES: WHICH IS WHAT I JUST SAID,
14 MARIA. I CANNOT COMMENT, BUT I CAN COMMENT ABOUT
15 WHAT THE BOARD OF REGENTS IS GOING TO BE CONSIDERING
16 TOMORROW WHICH LENDS ITSELF TO WHAT YSABEL AND
17 OTHERS HAVE BEEN TALKING ABOUT. AND THAT IS WE ARE
18 NOT THE ONLY ONES THAT ARE CONCERNED ABOUT
19 DIVERSITY. FORTY-FIVE PERCENT OF THE PROSPECTIVE
20 FRESHMEN OF THE 132,000, THE LARGEST CLASS EVER
21 ADMITTED TO THE UNIVERSITY OF CALIFORNIA, WERE
22 LOW-INCOME, 45 PERCENT WERE THE FIRST IN THEIR
23 FAMILIES TO ATTEND A FOUR-YEAR INSTITUTION, AND THE
24 CAMPUSES ALSO ADMITTED THE LARGEST AMOUNT, 28,000,
25 FROM THE COMMUNITY COLLEGE LEVEL. SO CLEARLY OUR

BETH C. DRAIN, CA CSR NO. 7152

1 UNIVERSITY IS MOVING IN THE RIGHT DIRECTION.

2 DO WE HAVE A LOT OF MORE WORK TO DO? YES,
3 ESPECIALLY WITH ONLY 5 PERCENT OF THE APPLICANTS
4 ADMITTED WERE AFRICAN-AMERICAN. WE ARE STILL
5 WOEFULLY BEHIND IN THAT ARENA, BUT AT LEAST WE SEE
6 SOME INCREASE IN THE LATINOS TO 37 PERCENT.

7 SO DIVERSITY IS IMPROVING. AND ESPECIALLY
8 MAKING SURE THAT RECRUITMENT, AS YSABEL WAS
9 CONCERNED ABOUT, AS I HAVE BEEN AS WELL, THAT WE
10 RECRUIT THESE YOUNG PEOPLE, ESPECIALLY DIVERSE
11 STUDENTS, INTO THE SCIENCE FIELD AND INTO THE
12 GRADUATE FIELD AND HOPEFULLY INTO THE ACADEMIC AND
13 INSTITUTIONAL FIELD AS WELL. THAT WAS WHAT I WANTED
14 TO REPORT.

15 CHAIRMAN THOMAS: OKAY. THANK YOU, ART.
16 OTHER COMMENTS FROM MEMBERS OF THE BOARD? OKAY. WE
17 HAVE A MOTION WITH A FRIENDLY --

18 MS. DURON: J.T., HANG ON. YSABEL AGAIN.

19 CHAIRMAN THOMAS: YES, YSABEL.

20 MS. DURON: NOT TRYING TO BE RUDE, BUT I
21 WAS WAITING FOR OTHERS IN CASE THEY WANTED TO SPEAK.
22 SIMPLY WANTED TO ADD TO ART'S COMMENT. I THINK IT
23 IS REALLY CRUCIAL TO UNDERSTAND THAT SOMETIMES THE
24 CHALLENGES FOR THESE STUDENTS OF COLOR COMING OUT
25 HAVE DOUBLE AND TRIPLE RESPONSIBILITIES ON THEIR

BETH C. DRAIN, CA CSR NO. 7152

1 HANDS. THEY'RE WORKING PART TIME TO HELP THEIR
2 FAMILIES. THERE ARE A LOT OF OTHER CHALLENGES.
3 SOMETIMES THEY DON'T EVEN TRUST THEIR OWN ABILITIES
4 TO TAKE ON SOMETHING LIKE SCIENCE. AND I THINK THAT
5 BEING IN THESE SMALL KINDS OF COLLEGES THAT CAN
6 MAYBE NURTURE THOSE HOPES AND DREAMS AND SHOW THEM
7 THAT IT'S OKAY TO FAIL, IT'S JUST ANOTHER LEARNING
8 OPPORTUNITY.

9 SO I LIKE THE IDEA OF SUPPORTING THESE --
10 THE COMMUNITY COLLEGES WHERE KIDS CAN LEARN TO TRUST
11 THEMSELVES AND BELIEVE IN THEMSELVES AND THEN TAKE
12 ON THE GIANTS. SO I WANT US NEVER TO -- I WANT US
13 TO HELP THESE SMALL COLLEGES BE BEST SO THAT THEY
14 CAN, IN FACT, NURTURE THIS NEXT GENERATION OF
15 SCIENTISTS THAT WE ARE HOPING WILL BE THERE.

16 CHAIRMAN THOMAS: THANKS, YSABEL. AND,
17 AGAIN, I WOULD REFER EVERYBODY TO THE LETTER BY THE
18 FORMER STUDENT WHICH GETS EXACTLY TO THAT POINT
19 ABOUT HOW WELL IT PREPARED HIM AND MANY OF HIS
20 COLLEAGUES FOR TAKING ON THE WORLD, WHICH IS EXACTLY
21 WHAT WE HOPE HAPPENS IN THIS PROGRAM.

22 OKAY. SO WE HAVE A MOTION WITH A FRIENDLY
23 AMENDMENT ON THE TABLE. KEVIN, DO YOU HAVE THE
24 PHRASING FOR THE FRIENDLY AMENDMENT SO THAT WE KNOW
25 EXACTLY WHAT IS BEING MOVED AT THIS POINT?

BETH C. DRAIN, CA CSR NO. 7152

1 MR. MARKS: WE WERE TRYING TO CAPTURE IT
2 HERE ON OUR SIDE. AND IT'S -- WE BELIEVE THE
3 AMENDMENT IS -- SORRY. I'M TRYING TO READ MARIA'S
4 WRITING AS WE WERE GOING BACK AND FORTH. THAT AS
5 PROPOSED THAT THE PROGRAM DEVELOP A DOCUMENTED,
6 SUCCESSFUL MENTORSHIP PROGRAM WITHIN THE FIRST YEAR.
7 SO THAT WAS THE CONDITION UPON WHICH -- SO HE WOULD
8 ADD THAT, I BELIEVE, OS, TO THE ORIGINAL MOTION.

9 SO IT'S APPROVAL WITH THE CONDITION THAT
10 THE PROGRAM DEVELOP A DOCUMENTED, SUCCESSFUL
11 MENTORSHIP PROGRAM WITHIN THE FIRST YEAR.

12 DR. STEWARD: YES, CORRECT.

13 CHAIRMAN THOMAS: AND REPORT BACK,
14 CORRECT, OS?

15 DR. STEWARD: WELL, CONSIDER THIS A
16 MILESTONE. IT'S THE SAME KIND OF THING THAT WE
17 COULD DO IN RESEARCH GRANTS AND CLINICAL GRANTS AND
18 SO FORTH. THIS WOULD BE CONSIDERED THEIR MILESTONE
19 FOR CONTINUATION OF FUNDING DURING THIS PERIOD OF
20 TIME. AND I'M NOT SUGGESTING THAT THIS COME BACK TO
21 THE BOARD OR TO THE GRANTS WORKING GROUP. THIS IS
22 SOMETHING THAT I'M SUGGESTING THAT THEY DO IN
23 CONJUNCTION WITH CIRM STAFF AND THAT CIRM STAFF
24 REVIEW WHATEVER THEY PUT TOGETHER AND THAT CIRM
25 STAFF MAKE THAT DECISION OF WHETHER THE PROGRAM

BETH C. DRAIN, CA CSR NO. 7152

1 ACTUALLY MEETS THE GOAL. I'M NOT SETTING A
2 PARTICULAR THRESHOLD HERE, BUT, AGAIN, WE WANT TO
3 HELP THEM SUCCEED. AND AS YSABEL SAID, THESE ARE
4 STUDENTS WHO MAY NOT FEEL CONFIDENT IN THEMSELVES
5 AND MAY NEED EXTRA HELP HERE. SO I THINK THAT THIS
6 WILL BE A WAY OF ENSURING IT. THANK YOU.

7 CHAIRMAN THOMAS: OKAY.

8 DR. MARKS: J.T., I BELIEVE THE WORDING
9 PROVIDES FLEXIBILITY ON THE PART OF THE CIRM STAFF
10 TO DETERMINE THE LEVEL OF DOCUMENTATION AND THE
11 DETERMINATION OF SUCCESS IF THAT'S OKAY WITH YOU AND
12 THE BOARD.

13 CHAIRMAN THOMAS: SURE. OKAY. GREAT.
14 ALL RIGHT. SO WE HAVE A MOTION AS AMENDED AND A
15 SECOND. WE HAVE NO FURTHER BOARD COMMENT. DO WE
16 HAVE PUBLIC COMMENT ON THIS MOTION?

17 MS. BONNEVILLE: WE DO HAVE PUBLIC
18 COMMENT, J.T.

19 CHAIRMAN THOMAS: OKAY.

20 MS. BONNEVILLE: I THINK BARBARA WOULD BE
21 THE FIRST ONE. SO IF YOU COULD UNMUTE YOURSELF, AND
22 YOU HAVE THREE MINUTES FOR PUBLIC COMMENT.

23 DR. DES ROCHERS: WELL, I'M NOT GOING
24 TO -- I PLANNED MY PUBLIC COMMENTS RIGHT TO THREE
25 MINUTES, BUT I'M NOT GOING TO SAY THEM BECAUSE ALL

BETH C. DRAIN, CA CSR NO. 7152

1 OF YOU HAVE EXPRESSED VERY CLEARLY AND THOUGHTFULLY
2 JUST WHAT I WAS GOING TO SAY. SO I THINK I'M GOING
3 TO LEAVE IT AT THAT. BUT I DO WANT YOU TO KNOW THAT
4 OUR GOAL AT OUR CLASSES HAS ALWAYS BEEN TO HELP
5 STUDENTS GAIN CONFIDENCE. THIS IS THE MOST CRITICAL
6 FACTOR THAT WE FOUND. AND IT GOES A LONG WAY TO
7 ENSURING THEIR SUCCESS, AND OUR STUDENTS HAVE BEEN
8 SUCCESSFUL.

9 I HAVE WRITTEN DOWN YOUR SUGGESTIONS
10 REGARDING STANDARDIZING THE ONRAMP OF STUDENTS, AND
11 WE WILL TAKE THAT SERIOUSLY. I DID WANT TO SAY THAT
12 OUR STUDENTS WERE GIVEN QUITE A BIT OF SUPPORT
13 DURING THE PROCESS IN THE FIRST CIRM INTERNSHIP, AND
14 WE DIDN'T REALLY LOSE ANY STUDENTS.

15 WE ARE VERY WELL AWARE OF THAT LACK OF
16 CONFIDENCE. AND ONE OF THE THINGS WE TRY TO DO IN
17 OUR -- THROUGHOUT OUR CLASSES, OUR LAB CLASSES, IS
18 EXPOSE STUDENTS TO SO MUCH THAT THEY BUILD THAT
19 CONFIDENCE IN THEMSELVES. AND THAT'S SO CRITICAL TO
20 US. BUT I DO WANT TO THANK YOU VERY MUCH FOR YOUR
21 COMMENTS.

22 IF WE ARE FUNDED, WE WILL DEFINITELY WORK
23 WITH THE CITY COLLEGE OF SAN FRANCISCO AS THEY DO
24 HAVE A NICE PROCESS THERE, BUT BASICALLY I JUST WANT
25 TO THANK YOU FOR YOUR THOUGHTS. I FEEL THAT WE HAVE

BETH C. DRAIN, CA CSR NO. 7152

1 A VERY STRONG PROGRAM, AND IN FACT, GIVEN THE
2 TRAINING THAT WE AFFORD, WE REALLY DO OFFER THE
3 BREADTH AND DEPTH OF TRAINING THAT I THINK IS
4 CRITICAL FOR SUCCESSFUL CIRM INTERNSHIPS. SO THANK
5 YOU VERY MUCH, AND I WILL ALLOW THE EXTRA TIME FOR
6 MY STUDENTS THAT WANTED TO JOIN. THANK YOU.

7 CHAIRMAN THOMAS: BARBARA, COULD YOU JUST
8 GIVE YOUR FULL NAME AND TITLE FOR EVERYBODY JUST SO
9 THEY KNOW EXACTLY WHO YOU ARE?

10 DR. DES ROCHERS: YES. MY NAME IS BARBARA
11 DESROCHERS, AND I AM THE PROGRAM DIRECTOR FOR
12 BIOTECHNOLOGY AT BERKELEY CITY COLLEGE. AND I THINK
13 MOST OF YOU PROBABLY KNOW THAT BERKELEY CITY COLLEGE
14 IS PART OF THE PERALTA COMMUNITY COLLEGE DISTRICT
15 WHICH INCLUDES FOUR COLLEGES THAT SERVE THE EAST
16 BAY. AND WE ARE REALLY THE ONLY COLLEGE THAT OFFERS
17 THIS LEVEL OF A BIOTECHNOLOGY TRAINING IN THE EAST
18 BAY IN THE COMMUNITY COLLEGE SYSTEM.

19 CHAIRMAN THOMAS: OKAY. THANK YOU VERY
20 MUCH FOR YOUR COMMENTS.

21 NEXT, BRIAN, IF YOU COULD GIVE YOUR FULL
22 NAME AND AFFILIATION PLEASE.

23 MR. SIEMONS: HELLO. MY NAME IS BRIAN
24 SIEMONS. I AM A STAFF RESEARCH ASSOCIATE AT THE
25 UNIVERSITY OF CALIFORNIA BERKELEY. I WAS A 2015

BETH C. DRAIN, CA CSR NO. 7152

1 CIRM BRIDGES AWARDEE.

2 I WOULD LIKE TO KIND OF ADD TO THE WHOLE
3 SELECTING OF YOUR LAB. I DID FIND IT KIND OF
4 ENJOYABLE AND A SENSE OF ESTABLISHING CONFIDENCE TO
5 EXPLORE DIFFERENT LABORATORIES FOR MY OWN. I
6 REACHED OUT TO PI'S, I INTERNED WITH THEM, I KIND OF
7 REVIEWED WHO I WANT TO JOIN. AND I THOUGHT THAT WAS
8 KIND OF MAYBE A PROBLEM, AND I AGREE WITH YOU GUYS
9 THAT IT WOULD BE GOOD TO KIND OF RELAY THIS
10 INFORMATION BACK, BUT IT WAS A VERY ENJOYABLE
11 PROGRAM.

12 YOU MAY THINK LIKE A CITY COLLEGE DOESN'T
13 HAVE MUCH TO OFFER, BUT BERKELEY CITY COLLEGE HAS
14 ONE OF THE MOST ADVANCED SCIENTIFIC LABORATORIES
15 THAT I'VE EVER SEEN. I'M WORKING AT UC BERKELEY AND
16 I'M ALSO WORKING FOR A START-UP HERE IN THE STANLEY
17 HALL QB3 GARAGE ALL THANKS TO CIRM. SO I WAS DOING
18 MY TEN-MONTH INTERNSHIP IN KEVIN HEALY'S LAB AT UC
19 BERKELEY USING STEM CELLS, IPS-DERIVED
20 CARDIOMYOCYTES THAT I DIFFERENTIATED IN HIS LAB.
21 I'VE ALWAYS BEEN TOLD I'M SO EXCELLENTLY TRAINED.
22 EVERY POST-DOC I'VE WORKED WITH AND GRAD STUDENTS,
23 I'VE ACTUALLY TRAINED POST-DOCS AND GRAD STUDENTS
24 ALL THANKS TO THE PROGRAM.

25 I WOULD JUST LIKE TO EXPRESS THAT BERKELEY

BETH C. DRAIN, CA CSR NO. 7152

1 CITY COLLEGE IS REALLY ONE OF THE MOST ADVANCED
2 PROGRAMS THAT THERE IS TO OFFER FOR A CITY COLLEGE,
3 AND I JUST REALLY WOULD LIKE TO HAVE IT
4 RECONSIDERED. OBVIOUSLY NOT EVERYBODY HAS THE
5 ABILITY TO GET INTO A UNIVERSITY. I MYSELF AM ONE
6 OF THESE INCLUDED THERE, AND I FOUND THIS PROGRAM AT
7 BERKELEY CITY COLLEGE -- AND I CHANGED MY NURSING
8 CAREER TO GO INTO THIS ROUTE. AND I KNEW NOTHING OF
9 LAB TECHNIQUES OR ANYTHING, AND IT VERY WELL
10 PREPARED ME FOR WHAT WAS TO COME. I SUCCEEDED IN MY
11 TEN-MONTH INTERNSHIP. I PUBLISHED A PAPER IN STEM
12 CELL -- IT'S ACTUALLY A NEW NATURE
13 COMMUNICATION -- NATURE STEM CELL BIOENGINEERING
14 PAPER WHEN I WAS DOING MY INTERNSHIP HERE. SINCE
15 THEN I'VE PUBLISHED, CO-AUTHORED WITH NUMEROUS
16 PUBLICATIONS WITH KEVIN'S LAB WITH UCSF
17 COLLABORATORS, ADVANCING THE DRUG DISCOVERY PIPELINE
18 WITH OUR CARDIAC CHIP.

19 I THINK BERKELEY CITY COLLEGE IS PRECISELY
20 WHERE THIS KIND OF INVESTMENT NEEDS TO BE PUSHED TO.
21 AND I THINK, LIKE BARBARA SAID, YOU GUYS HAVE
22 ADDRESSED A LOT OF YOUR KIND OF CONCERNS WITH THE
23 PROGRAM THE WAY IT WAS KIND OF STRUCTURED, BUT I DO
24 THINK THAT'S A SIMPLE THING THAT WE CAN CORRECT
25 BECAUSE WE HAVE MANY COLLABORATORS THAT THEY HAVE

BETH C. DRAIN, CA CSR NO. 7152

1 ACCESS TO. THEY HAVE THE DIFFERENT EQUIPMENT AND
2 EVERYTHING NEEDED TO REALLY PUSH THE BOUNDARIES FOR
3 PEOPLE THAT AREN'T REALLY GETTING INTO THESE
4 SYSTEMS, RIGHT. LIKE A LOT OF YOUNG KIDS, NEW KIDS,
5 OLDER PEOPLE, THEY CHANGE THEIR CAREER PATH MIDLIFE
6 OR SOMETHING LIKE THIS LIKE MYSELF AND IT MAY BE
7 KIND OF DIFFICULT TO GET INTO A UNIVERSITY. MOST OF
8 THESE APPLICATIONS ARE PRETTY ADVANCED, AND YOU
9 DON'T REALLY SEE UNLESS YOU GET INTO A UNIVERSITY OR
10 A START-UP OR SOMETHING IN INDUSTRY, AND I THINK A
11 LOT OF THESE KIND OF UNDERREPRESENTED PEOPLE WOULD
12 REALLY BENEFIT FROM KEEPING THIS PROGRAM ACTIVE AT
13 BERKELEY CITY COLLEGE.

14 CHAIRMAN THOMAS: OKAY. THANK YOU VERY
15 MUCH, BRIAN. AND WE KNOW THAT YOUR COMMENT THAT WE
16 MAY NOT THINK THAT COMMUNITY COLLEGES HAVE A GREAT
17 SETUP, WE ARE FULLY AWARE THAT THE COMMUNITY
18 COLLEGES HAVE TREMENDOUS PROGRAMS. WE ARE A HUNDRED
19 FIFTY PERCENT IN SUPPORT OF ALL THAT THEY DO. AND
20 IT'S VERY GOOD TO HEAR ABOUT YOUR PERSONAL
21 EXPERIENCE THERE AS INDICATIVE OF THE STRENGTH OF
22 THE PROGRAM AND EXACTLY WHAT YOU WERE ABLE TO LEARN.
23 SO THANK YOU.

24 JASON, NEXT PLEASE. NAME AND AFFILIATION
25 FIRST.

BETH C. DRAIN, CA CSR NO. 7152

1 MR. LUKE: HELLO. MY NAME IS JASON, AND I
2 AM ALSO A CIRM BRIDGES STUDENT. I WAS ACTUALLY IN
3 THE CLASS WITH BRIAN.

4 I WOULD LIKE TO SPEAK ON BEHALF OF BCC IN
5 THAT I'M AN UNCONVENTIONAL STUDENT. I CAME TO BCC
6 AFTER MY TIME IN THE MARINE CORPS, AND I WAS ABLE TO
7 COME INTO A CLASS THAT WAS FILLED WITH A DIVERSE
8 GROUP OF STUDENTS. SOME HAD CHILDREN, SOME WERE
9 WORKING FULL TIME, SOME PART TIME, SOME PEOPLE WERE
10 ON THEIR TRACK TO GO TO MEDICAL SCHOOL, NURSING
11 SCHOOL.

12 MYSELF, I HAD AMBITIONS OF DOING AN
13 ENGINEERING PROGRAM AT BERKELEY. AND I FELT THAT
14 THE PROGRAM, THE BIOTECH PROGRAM, WAS PERFECT. IT
15 TRAINED ME. THE LABS WERE EXCELLENT. I GOT A LOT
16 OF PERSONAL ATTENTION. THE TEACHERS WERE
17 PASSIONATE. AND NOT ONLY WAS I ABLE TO USE MY GI
18 BILL TO ATTAIN THE MECHANICAL ENGINEERING DEGREE
19 THAT I WANTED, I WAS ACTUALLY ABLE TO WALK AWAY WITH
20 A BIOTECH, AN A.S. IN BIOTECH, WHICH SERVED ME
21 GREATLY WITH THE EVENTS THAT WE'VE ALL BEEN
22 EXPERIENCING THIS PAST YEAR WITH THE COVID. THE
23 ONLY JOBS THAT WERE ACTUALLY NOT AFFECTED WERE
24 THE -- WAS THE BIOTECH INDUSTRY.

25 SO AS I GRADUATED IN 2020 AND PEOPLE WERE

BETH C. DRAIN, CA CSR NO. 7152

1 WONDERING HOW LONG WAS IT GOING TO TAKE TO FIND A
2 JOB, I WAS ABLE TO RELY ON MY BIOTECHNOLOGY DEGREE
3 AND FIND A JOB ALMOST IMMEDIATELY. SO NOW I'M ABLE
4 TO BUILD BOTH SKILL SETS SIMULTANEOUSLY, ONE WITH
5 THE ENGINEERING DEGREE, THE OTHER WITH THE BIOTECH
6 DEGREE. AND THAT IS BECAUSE OF THE CIRM BRIDGES
7 PROGRAM AT BCC.

8 I CONSIDERED OTHER SCHOOLS IN THE AREA.
9 AND AFTER VISITING THEIR CAMPUSES, IT JUST WASN'T
10 FOR ME. EITHER THE SCHOOLS WERE TOO LARGE, SUCH AS
11 CITY COLLEGE OF SAN FRANCISCO WASN'T A GREAT FIT FOR
12 ME MAINLY BECAUSE THE CAMPUS WAS SO LARGE. I WENT
13 TO VISIT BCC. THE LABS WERE -- IT WAS NIGHT AND
14 DAY. ONE LOOKED LIKE I WOULD COMPARE IT TO MAYBE
15 LIKE A HIGH SCHOOL SETUP FROM THE '90S, AND THE
16 BERKELEY SETUP WAS MORE IN LINE WITH WHAT I WANTED
17 TO DO IN TERMS OF PREPARING ME FOR THE INDUSTRY.

18 AND IN TERMS OF THE SELF-SELECTION IN
19 TERMS OF BEING ABLE TO PICK YOUR LAB, I THINK THAT'S
20 GREAT. I THINK IT PREPARED ME IN TERMS OF NO ONE
21 TOLD ME WHICH WAY TO GO. I WANTED TO GO TO
22 BERKELEY. SO INSTEAD OF SOME OF MY OTHER CLASSMATES
23 WERE INTERESTED IN INDUSTRY, SO WHILE THEY WERE
24 LOOKING FOR INTERNSHIPS IN INDUSTRY, I WAS ABLE TO
25 GO TO BERKELEY AND PICK THREE DIFFERENT LABS AND GO

BETH C. DRAIN, CA CSR NO. 7152

1 ON INTERVIEWS WITH THREE DIFFERENT PI'S.

2 I'M SORRY. MY TIME IS UP. BUT
3 ESSENTIALLY IT GAVE ME THE CONFIDENCE BECAUSE NOBODY
4 HANDED ME A JOB AFTER MY GRADUATION. I HAD TO GO
5 OUT ON INTERVIEWS. SO THAT BEING ABLE TO SELECT MY
6 INTERNSHIP, IT GAVE ME THE CONFIDENCE TO GET OUT
7 THERE AND EARN MY KEEP.

8 CHAIRMAN THOMAS: RIGHT. THANK YOU VERY
9 MUCH, JASON. ANY OTHER PUBLIC COMMENT? HEARING
10 NONE, MARIA, WILL YOU PLEASE CALL THE ROLL.

11 MS. BONNEVILLE: DAN BERNAL.

12 MR. BERNAL: AYE.

13 MS. BONNEVILLE: ANNE-MARIE DULIEGE.

14 DR. DULIEGE: AYE.

15 MS. BONNEVILLE: YSABEL DURON.

16 MS. DURON: AYE.

17 MS. BONNEVILLE: MARK FISCHER-COLBRIE.

18 DR. FISCHER-COLBRIE: YES.

19 MS. BONNEVILLE: FRED FISHER.

20 DR. FISHER: AYE.

21 MS. BONNEVILLE: DAVID HIGGINS.

22 DR. HIGGINS: YES.

23 MS. BONNEVILLE: STEVE JUELGAARD.

24 MR. JUELGAARD: YES.

25 MS. BONNEVILLE: DAVE MARTIN. LAUREN

BETH C. DRAIN, CA CSR NO. 7152

1 MILLER ROGEN. ADRIANA PADILLA.
2 DR. PADILLA: YES.
3 MS. BONNEVILLE: JOE PANETTA.
4 MR. PANETTA: YES.
5 MS. BONNEVILLE: AL ROWLETT.
6 MR. ROWLETT: YES.
7 MS. BONNEVILLE: OS STEWARD.
8 DR. STEWARD: YES.
9 MS. BONNEVILLE: JONATHAN THOMAS.
10 CHAIRMAN THOMAS: YES.
11 MS. BONNEVILLE: KAROL WATSON. KAROL,
12 YOU'RE ON MUTE.
13 MOTION CARRIES.
14 CHAIRMAN THOMAS: THANK YOU, MARIA. OKAY.
15 SO THAT WILL NOW ELEVATE THAT APPLICATION TO TIER I.
16 THE NEXT STEP IN THIS PROCESS, DO WE HAVE
17 ANY MOTIONS TO LOWER ANY OF THE TIER I PROJECTS TO
18 TIER II?
19 HEARING NONE, DO WE HAVE NOW AN OMNIBUS
20 MOTION TO APPROVE THE SLATE OF 15 GRANTS LISTED ON
21 YOUR SCREEN?
22 MR. ROWLETT: SO MOVED. AL ROWLETT.
23 CHAIRMAN THOMAS: THANK YOU, AL. DO WE
24 HAVE A SECOND?
25 DR. HIGGINS: DAVID IN SAN DIEGO.

BETH C. DRAIN, CA CSR NO. 7152

1 CHAIRMAN THOMAS: THANK YOU, DAVID.

2 COMMENTS FROM MEMBERS OF THE BOARD? ANY COMMENTS
3 FROM MEMBERS OF THE PUBLIC? HEARING NONE, MARIA,
4 WILL YOU PLEASE CALL THE ROLL.

5 MS. BONNEVILLE: SURE. AS A REMINDER, I
6 WOULD ASK BOARD MEMBERS TO ANSWER WITH YEA OR NAY
7 EXCEPT FOR THOSE WITH WHICH I HAVE A CONFLICT.

8 DAN BERNAL.

9 MR. BERNAL: YEA.

10 MS. BONNEVILLE: LEONDRA CLARK-HARVEY.
11 ANNE-MARIE DULIEGE.

12 DR. DULIEGE: YES.

13 MS. BONNEVILLE: YSABEL DURON.

14 MS. DURON: YEA.

15 MS. BONNEVILLE: MARK FISCHER-COLBRIE.

16 DR. FISCHER-COLBRIE: YEA.

17 MS. BONNEVILLE: FRED FISHER.

18 DR. FISHER: YEA.

19 MS. BONNEVILLE: DAVID HIGGINS.

20 DR. HIGGINS: YIPPEE YEA.

21 MS. BONNEVILLE: STEVE JUELSGAARD.

22 MR. JUELSGAARD: YES.

23 MS. BONNEVILLE: DAVE MARTIN. CHRISTINE
24 MIASKOWSKI.

25 DR. MIASKOWSKI: YES, EXCEPT FOR THOSE

BETH C. DRAIN, CA CSR NO. 7152

1 WITH WHICH I HAVE A CONFLICT.

2 MS. BONNEVILLE: LAUREN MILLER ROGEN.

3 ADRIANA PADILLA.

4 DR. PADILLA: YES.

5 MS. BONNEVILLE: JOE PANETTA.

6 MR. PANETTA: YES.

7 MS. BONNEVILLE: AL ROWLETT.

8 MR. ROWLETT: FIFTEEN YEAS.

9 MS. BONNEVILLE: OS STEWARD.

10 DR. STEWARD: YES, EXCEPT FOR THOSE WITH

11 WHICH I HAVE A CONFLICT.

12 MS. BONNEVILLE: JONATHAN THOMAS.

13 CHAIRMAN THOMAS: YES.

14 MS. BONNEVILLE: ART TORRES.

15 MR. TORRES: AYE, EXCEPT FOR THOSE WITH

16 WHICH I HAVE A CONFLICT.

17 MS. BONNEVILLE: KAROL WATSON.

18 DR. WATSON: YES, EXCEPT FOR THOSE FOR

19 WHICH I HAVE A CONFLICT.

20 MS. BONNEVILLE: THANK YOU VERY MUCH. THE

21 MOTION CARRIES.

22 CHAIRMAN THOMAS: THANK YOU.

23 CONGRATULATIONS TO ALL 15 APPLICANTS. WE, AS

24 ALWAYS, AVIDLY LOOK FORWARD TO HEARING ABOUT HOW

25 YOUR PROGRAMS PROCEED AND WISH YOU THE BEST OF LUCK.

BETH C. DRAIN, CA CSR NO. 7152

1 OKAY. NOW I'M GOING TO TURN THIS OVER TO
2 OS FOR NO. 4, CONSIDERATION OF APPLICATIONS
3 SUBMITTED IN RESPONSE TO CLINICAL TRIAL STAGE
4 PROJECT PROGRAM ANNOUNCEMENTS. OS.

5 DR. STEWARD: AND I WILL IMMEDIATELY TURN
6 IT OVER TO GIL FOR A PRESENTATION ON THIS
7 APPLICATION.

8 DR. SAMBRANO: OKAY. THANK YOU VERY MUCH.
9 LET ME JUST SHARE THAT PRESENTATION. OKAY. SO
10 THESE ARE THE RECOMMENDATIONS FOR APPLICATIONS
11 SUBMITTED TO THE CLINICAL PROGRAM. AND AS YOU MAY
12 RECALL, THE CLINICAL STAGE PROGRAM OFFERS THREE
13 DIFFERENT TYPES OF OPPORTUNITIES, THOSE FOR
14 IND-ENABLING WORK, WHICH IS THE CLIN1; AND FOR
15 CLINICAL TRIAL WORK, WHICH IS THE CLIN2; AS WELL AS
16 SUPPLEMENTAL ACCELERATING ACTIVITIES, WHICH IS THE
17 CLIN3.

18 SO THIS APPLICATION WE ARE CONSIDERING
19 TODAY IS A CLINICAL TRIAL THAT FALLS UNDER THE CLIN2
20 PROGRAM. AND MORE SPECIFICALLY, IT FALLS UNDER OUR
21 ALLOCATION FOR OUR SICKLE CELL DISEASE UNDER OUR
22 COLLABORATION WITH THE NIH, NHLBI. AND SO THERE IS
23 AN ALLOCATION THAT WAS MADE FOR THAT PARTNERSHIP OF
24 \$30 MILLION. AND SO WHAT I'M SHOWING YOU HERE IS
25 AMOUNT REQUESTED TODAY FOR THIS PARTICULAR

BETH C. DRAIN, CA CSR NO. 7152

1 APPLICATION IS 8.4 MILLION. WE HAVE APPROVED
2 ALREADY 12.6 PREVIOUSLY, WHICH WOULD LEAVE 9 MILLION
3 IN THAT ALLOCATION REMAINING.

4 THE REVIEW CRITERIA THAT WERE UTILIZED FOR
5 ASSESSING THIS PROJECT ALONG WITH OTHER CLINICAL
6 TRIAL STAGE PROJECTS FALL ACROSS THESE FIVE
7 QUESTIONS: DOES THE PROJECT HOLD THE NECESSARY
8 SIGNIFICANCE AND POTENTIAL FOR IMPACT? IS THE
9 RATIONALE SOUND? IS THE PROJECT WELL-PLANNED AND
10 DESIGNED? IS IT FEASIBLE, INCLUDING THE OVERALL
11 TEAM AND RESOURCES AVAILABLE TO THE PROJECT? AND
12 THEN, FINALLY, DOES THE PROJECT ADDRESS THE NEEDS OF
13 UNDERSERVED COMMUNITIES?

14 THE SCORING SYSTEM THAT IS USED BASED ON
15 THOSE CRITERIA IS ONE OF A 1, 2, OR A 3. THOSE THAT
16 RECEIVE A SCORE 1 MEANS THAT THEY HAVE EXCEPTIONAL
17 MERIT AND WARRANT FUNDING. THEY MIGHT HAVE SOME
18 MINOR RECOMMENDATIONS OR ADJUSTMENTS, BUT OTHERWISE
19 DON'T NEED FURTHER REVIEW BY THE GRANTS WORKING
20 GROUP. SCORE OF 2 MEANS IT NEEDS IMPROVEMENT, AND
21 THESE APPLICANTS GET THE OPPORTUNITY TO REVISE THEIR
22 APPLICATION BEFORE RETURNING TO THE GRANTS WORKING
23 GROUP. OR A SCORE OF 3 WHERE IT IS SUFFICIENTLY
24 FLAWED THAT IT DOESN'T WARRANT FUNDING AT THIS TIME.

25 THERE ARE A COUPLE OF ELEMENTS IN THE CIRM

BETH C. DRAIN, CA CSR NO. 7152

1 APPLICATION REVIEW THAT I JUST WANTED TO MENTION. I
2 ALREADY DID MENTION THE ADDRESSING NEEDS OF
3 UNDERSERVED COMMUNITIES. AND THIS SECTION IS THE
4 APPLICANT'S PLAN FOR OUTREACH AND ENROLLMENT OF A
5 DIVERSE PATIENT COHORT THAT ACCOUNTS FOR RACIAL,
6 ETHNIC, AND GENDER DIVERSITY IN THE CLINICAL TRIAL.
7 AND SO THIS ELEMENT IS ONE THAT'S REVIEWED BY THE
8 SCIENTIFIC MEMBERS AS WELL AS PATIENT ADVOCATE
9 MEMBERS, BUT IS INCORPORATED INTO THE SCORE OF 1, 2,
10 OR 3. SO THAT ELEMENT, AS MENTIONED, IS PART OF THE
11 REVIEW CRITERIA.

12 WE HAVE ALSO BEEN REVIEWING AND DISCUSSING
13 DIVERSITY, EQUITY, AND INCLUSION MORE BROADLY. THIS
14 IS A MORE HOLISTIC VIEW IN WHICH THE APPLICANT TEAM
15 INCORPORATES AN EXPLANATION OF HOW THE APPLICANT
16 TEAM INCORPORATES DIVERSE PERSPECTIVE AND EXPERIENCE
17 IN ORDER TO IMPROVE THE PROJECT AND ALSO BRING
18 MENTION OF HOW THEY VALUE DIVERSITY AND WHAT THE
19 TEAM OVERALL DOES TO BROADEN IT. AND SO THIS
20 SECTION IS EVALUATED AND SCORED BY OUR PATIENT
21 ADVOCATE NURSE MEMBERS OF THE BOARD AND IS SHOWN IN
22 THE DEI SCORE WHICH IS IN A RANGE OF ZERO TO TEN.

23 SO THIS PARTICULAR APPLICATION IS
24 CLIN2SCD-11722, WHICH IS A CELL AND GENE THERAPY FOR
25 SICKLE CELL DISEASE. IT IS A CD 34 POSITIVE

BETH C. DRAIN, CA CSR NO. 7152

1 HEMATOPOIETIC STEM CELL PRODUCT THAT IS GENETICALLY
2 MODIFIED TO CORRECT THE SICKLE CELL MUTATION. SO
3 THIS IS AUTOLOGOUS CELLS, SO THE CELLS FROM THE
4 PATIENT, THAT ARE CORRECTED FOR THAT POINT MUTATION.

5 THE INDICATION IS FOR INDIVIDUALS THAT
6 EXPERIENCE SEVERE SICKLE CELL DISEASE. AND THE GOAL
7 IS TO COMPLETE A PHASE 1 TRIAL TO ASSESS THE SAFETY
8 AND INITIAL EFFICACY OF THIS PRODUCT.

9 THE TOTAL FUNDS OR THE TOTAL COST OF THE
10 PROJECT IS ABOUT 16.8 MILLION. AND THIS IS EXPECTED
11 TO BE SHARED EQUALLY BY CIRM AND NHLBI AND EACH
12 CONTRIBUTING ABOUT 8.4 MILLION TO THE AWARD. AND
13 I'LL SPEAK MORE ABOUT THE NHLBI CONTRIBUTION IS
14 STILL PENDING FINAL APPROVAL, AND I WILL REFERENCE
15 THAT IN JUST A SECOND.

16 SO A LITTLE BACKGROUND ON SICKLE CELL
17 DISEASE. THE SICKLE CELL DISEASE AFFECTS
18 APPROXIMATELY 100,000 AMERICANS. IT IS PARTICULARLY
19 COMMON AMONG THOSE WITH SUB-SAHARAN AFRICAN
20 ANCESTRY, AFFECTING ONE IN 365 AFRICAN-AMERICAN
21 BIRTHS. GLOBALLY THERE ARE OVER 300,000 BABIES WHO
22 ARE BORN WITH SICKLE CELL DISEASE EACH YEAR.

23 SO WHAT IS THE VALUE PROPOSITION FOR THIS
24 PROPOSED THERAPY? THE ONLY CURRENT CURE IS AN
25 ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION,

BETH C. DRAIN, CA CSR NO. 7152

1 BUT DONOR AVAILABILITY IS QUITE LIMITED AND THERE'S
2 A HIGHER RISK OF COMPLICATIONS SUCH AS GRAFT VERSUS
3 HOST DISEASE THAT PATIENTS CAN EXPERIENCE. SO THE
4 PROPOSED AUTOLOGOUS THERAPY, BEING AUTOLOGOUS WOULD
5 VOID THE MEDICAL RISKS OF AN ALLOGENEIC TRANSPLANT,
6 AND BECAUSE IT AIMS TO CORRECT THE GENETIC MUTATION,
7 IT MAY ALSO PROVIDE A POTENTIAL CURE.

8 THIS IS A STEM CELL PROJECT BECAUSE THE
9 THERAPEUTIC CANDIDATE INCLUDES HEMATOPOIETIC STEM
10 CELLS.

11 THIS SLIDE GIVES YOU AN OVERVIEW OF SOME
12 OF THE PROJECTS THAT WE HAVE ACTIVE IN OUR PORTFOLIO
13 AT THE CLINICAL STAGE. SO WE ARE SUPPORTING QUITE A
14 FEW PROJECTS THAT SEEK TO HELP WITH OR ADDRESS
15 SICKLE CELL DISEASE IN SOME WAY. THERE'S A MIXTURE
16 OF BOTH AUTOLOGOUS AND ALLOGENEIC APPROACHES. THE
17 FIRST ONE LISTED IS ACTUALLY THE PRECURSOR TO THIS
18 PARTICULAR GRANT APPLICATION. THIS SUPPORTED THE
19 IND-ENABLING WORK, AND THIS PARTICULAR APPLICATION
20 NOW SEEKS TO START THE PHASE 1 CLINICAL TRIAL.

21 THIS SLIDE IS A SUMMARY OF PREVIOUS CIRM
22 FUNDING TO THAT APPLICANT. SO INCLUDED IN THIS IS
23 THE IND-ENABLING AWARD, WHICH IS JUST ENDING, AND
24 THEY HAVE BEEN SUCCESSFUL AT ACHIEVING THE
25 MILESTONES AND FILING THE IND, WHICH HAS PERMITTED

BETH C. DRAIN, CA CSR NO. 7152

1 THEM TO GET TO THIS STAGE. THEY ALSO HAD A
2 TRANSLATIONAL AWARD THAT HELPED DEVELOP THE PRODUCT
3 THAT IS -- THAT WOULD BE STUDIED UNDER THIS CLINICAL
4 TRIAL.

5 SO FINALLY, THIS IS THE RECOMMENDATION
6 FROM THE GRANTS WORKING GROUP. THERE WERE 12
7 MEMBERS WHO GAVE THIS A SCORE OF 1, THREE THAT GAVE
8 IT A SCORE OF 2. SO THE OVERALL RECOMMENDATION IS
9 THAT OF A 1 TO FUND THIS. THE DEI SCORE WAS AN
10 EIGHT ON A SCALE OF ONE TO TEN. AND THE CIRM TEAM'S
11 RECOMMENDATION IS TO FUND THIS APPLICATION IN
12 ALIGNMENT WITH THE GRANTS WORKING GROUP
13 RECOMMENDATION.

14 AND SO I WILL NOTE HERE AGAIN THE AWARD
15 AMOUNT THAT YOU WOULD BE APPROVING FROM CIRM IS
16 ABOUT 8.4 MILLION, AND WE ARE EXPECTING NHLBI TO
17 CONTRIBUTE AN EQUAL AMOUNT, BUT IS PENDING FINAL
18 APPROVAL. THEY'VE ALREADY GONE THROUGH THEIR OWN
19 SCIENTIFIC REVIEW AND ASSESSMENT WHICH HAS ALL BEEN
20 FINE, SO THIS IS WHAT WE EXPECT TO BE JUST A FINAL
21 SIGN-OFF TO HAPPEN WITHIN THE NEXT FEW DAYS OR
22 WEEKS.

23 SO ONE NOTE IS THAT YOUR APPROVAL WILL BE
24 CONTINGENT UPON THAT NHLBI FINAL APPROVAL. AND WE
25 WILL NOT INITIATE THE LAUNCH OF THE AWARD UNTIL THAT

BETH C. DRAIN, CA CSR NO. 7152

1 CO-FUNDING DECISION IS CONFIRMED. AND IF FOR SOME
2 REASON NHLBI DOES NOT MEET THAT CO-FUNDING
3 CONTRIBUTION, WE WILL REQUIRE THE APPLICANT TO
4 SECURE CO-FUNDING OF THOSE PROJECT COSTS BEFORE
5 BRINGING IT TO YOU FOR A FINAL APPROVAL IF THAT
6 SHOULD HAPPEN. SO THAT IS THE PRESENTATION. BACK
7 TO YOU, DR. STEWARD.

8 DR. STEWARD: THANK YOU, GIL. SO JUST TO
9 SORT OF SAY SOMETHING BEFORE WE START THE
10 CONSIDERATION, AS SOMEONE WHO'S BEEN ON THE ICOC
11 FROM THE BEGINNING, I'LL JUST SAY THIS IS THE IMAGE
12 OF WHAT WE ALL THOUGHT MIGHT BE POSSIBLE BACK IN THE
13 BEGINNING, A PROJECT THAT MEETS A CLEAR UNMET
14 MEDICAL NEED, THAT MOVES THROUGH FUNDING OF
15 DIFFERENT STAGES OF RESEARCH, THE WONDERFUL ACTUALLY
16 CONTINUUM OF RESEARCH PROGRAMS THAT CIRM PUT
17 TOGETHER, WHICH IS UNIQUE AMONGST FUNDING AGENCIES
18 ALL THE WAY FROM EARLY DISCOVERY THROUGH TRANSLATION
19 TO THE INITIAL GRANTS -- THE CLINICAL GRANTS THAT WE
20 ARE SEEING AND REVIEW NOW. SO I JUST HAVE TO SAY
21 IT'S JUST SO GREAT TO SEE.

22 WITH THAT BACKGROUND, I'LL OPEN THE FLOOR
23 AND ASK IF THERE IS A MOTION TO FUND THIS PROPOSAL?

24 MR. ROWLETT: SO MOVED. THIS IS AL
25 ROWLETT.

BETH C. DRAIN, CA CSR NO. 7152

1 MR. BERNAL: SECOND. DAN BERNAL.

2 DR. STEWARD: THANK YOU. DISCUSSION BY
3 THE BOARD? MARIA, DO WE SEE ANY?

4 MS. BONNEVILLE: ANNE-MARIE HAS HER HAND
5 RAISED.

6 DR. STEWARD: SORRY. I CAN'T SEE. OKAY.
7 ANNE-MARIE.

8 DR. DULIEGE: JUST A QUESTION. I
9 APPRECIATE THE QUALITY OF THE GRANT. MY ONLY
10 QUESTION IS HOW MUCH TOTAL FUNDING HAVE WE DEVOTED
11 TO THIS IMPORTANT DISEASE? AND IS IT SOMEWHAT
12 DISPROPORTIONATE TO THE AMOUNT OF FUNDING THAT WE
13 MIGHT, CAN, SHOULD DEVOTE TO OTHER EQUALLY IMPORTANT
14 DISEASES?

15 DR. STEWARD: SO BEFORE TURNING THAT
16 QUESTION OVER TO CIRM, LET ME JUST SAY THAT THE
17 BOARD ACTUALLY ALLOCATED THE AMOUNT THAT WE DID
18 BASED ON A VOTE BY THE BOARD AND WE ALSO VOTED FOR
19 THE CO-FUNDING ARRANGEMENT THAT WE CURRENTLY HAVE.
20 SO THIS WHOLE THING WAS, IN FACT, SOMETHING THAT WAS
21 CONSIDERED IN ACTUALLY QUITE A LOT OF DETAIL BY THE
22 BOARD. BUT I'LL TURN IT OVER TO CIRM STAFF IN TERMS
23 OF THE ACTUAL NUMBERS.

24 DR. SAMBRANO: SO THE ACTUAL NUMBERS, THIS
25 IS APPROVED OUT OF THE 30 MILLION THAT WAS ALLOCATED

BETH C. DRAIN, CA CSR NO. 7152

1 AND WOULD MEAN AN INVESTMENT OF ABOUT 21 MILLION.
2 AS MENTIONED, THERE WERE OTHER AWARDS THAT WE HAVE
3 FUNDED THAT HAVE NOT NECESSARILY BEEN IN
4 COLLABORATION WITH NHLBI. I DON'T HAVE THE TOTAL
5 INVESTMENT NUMBER OF ALL OF THOSE, BUT IT WOULD
6 CERTAINLY EXCEED THE \$30 MILLION AMOUNT IN TOTAL.

7 DR. DULIEGE: THANK YOU.

8 DR. STEWARD: I SEE A HAND FROM FRED.

9 DR. FISHER: AS A NONSCIENTIST, YOU WILL
10 GET USED TO ME PREFACING MY REMARKS WITH THAT. I'M
11 CURIOUS ABOUT THE THREE THAT RANKED IT AS A 2. AND
12 IN SCANNING THE REMARKS, THERE WERE CONCERNS ABOUT
13 ENGRAFTMENT, WHICH I HAVE NO IDEA WHAT THAT IS, AND
14 THERE WERE CONCERNS ABOUT THE ENDPOINTS OF THE
15 TRIAL. SO I'M WONDERING IF SOMEONE CAN ADDRESS
16 THOSE CONCERNS AND WHY WE OUGHT NOT TO BE CONCERNED
17 ABOUT THAT IN APPROVING THE FUNDING IF THAT'S A
18 REASONABLE QUESTION.

19 DR. STEWARD: OH, IT'S A VERY REASONABLE
20 QUESTION. THANK YOU, FRED. AND I'LL TURN THAT OVER
21 TO GIL.

22 DR. SAMBRANO: YES. THANK YOU FOR THE
23 QUESTION. SO THE ENGRAFTMENT IS THE ABILITY OF THE
24 TRANSPLANT OR THESE HEMATOPOIETIC STEM CELLS TO STAY
25 IN THE BONE MARROW AND THEN GIVE RISE TO THE CELLS

BETH C. DRAIN, CA CSR NO. 7152

1 THEY HOPE TO. AND SO THE QUESTION AND/OR CONCERN IS
2 THAT IT MAY NOT WORK. IN OTHER WORDS, IF THEY DO
3 THE TRANSPLANT, THERE'S THE POSSIBILITY OR THE RISK
4 THAT ULTIMATELY THAT PATIENT WILL NOT EXPERIENCE THE
5 BENEFIT OF A CURE BY HAVING THOSE CELLS ENGRAFTED
6 INTO THE BONE MARROW. AND THIS COMES FROM JUST
7 PRELIMINARY DATA THAT IN MICE GAVE THE REVIEWERS
8 SOME CONCERN THAT THAT COULD BE THE CASE.

9 THE APPLICANTS, HOWEVER, HAVE MADE, I
10 THINK, A PRETTY REASONABLE ARGUMENT FOR WHY THEY
11 BELIEVE IT WILL. AND I THINK ULTIMATELY WHERE
12 REVIEWERS LANDED IN THE CONSIDERATION OF ALL THIS
13 WAS THAT YOU REALLY WON'T KNOW UNTIL YOU DO THE
14 TRIAL AND SEE IT IN THE PATIENTS. AND SO THERE IS
15 THE RISK WITH A LOT OF THESE STUDIES THAT THEY MAY
16 OR MAY NOT WORK, AND SO THAT WAS ONE OF THE CONCERNS
17 WITH THE ENGRAFTMENT.

18 THERE WERE SOME CONCERNS RELATED TO
19 POTENTIAL SAFETY, AND THAT AROSE DUE TO ISSUES ON
20 DIFFERENT TRIALS WHERE SOME OF THOSE WERE
21 TEMPORARILY HALTED BECAUSE OF MALIGNANCIES THAT
22 SEEMED TO HAVE OCCURRED WITH SIMILAR APPROACHES IN
23 SICKLE CELL DISEASE PATIENTS. THE REASON FOR THAT
24 IS NOT FULLY UNDERSTOOD. SINCE THAT TIME, THE HOLD
25 ON THOSE PROJECTS HAS BEEN FOR THE MOST PART

BETH C. DRAIN, CA CSR NO. 7152

1 RELEASED. AND SO THE FDA IS NOW ALLOWING THESE
2 TRIALS TO GO FORWARD. BUT HERE AGAIN, THIS IS ONE
3 OF THOSE ELEMENTS THAT IS NOW BEING INCORPORATED IN
4 TERMS OF BEING CAUTIOUS ABOUT THE SCREENING OF
5 PATIENTS THAT FIRST GO INTO THIS TRIAL AS WELL AS
6 ONGOING MONITORING OF THE PATIENTS FOR ANY POTENTIAL
7 RISK OF MALIGNANCY OR ANY CONCERNS OF MALIGNANCY AS
8 THEY GO INTO THIS TRIAL.

9 DR. FISHER: AND THE CONCERN ABOUT
10 ENDPOINTS THAT WAS EXPRESSED BY ONE REVIEWER, THAT
11 THE FEEDBACK REGARDING ENDPOINT DEFINITION WASN'T
12 RESPONDED TO, ARE WE CLEAR ABOUT WHAT THE ENDPOINTS
13 ARE?

14 DR. SAMBRANO: YEAH. SO I THINK THAT WAS
15 A KIND OF A CLEANUP COMMENT BECAUSE THEY EXPRESSED
16 IT SLIGHTLY DIFFERENTLY IN DIFFERENT PLACES IN THE
17 PROPOSAL. BUT THIS IS CLEARLY A SAFETY TRIAL WHERE
18 THE ENDPOINT IS REALLY ABOUT TESTING THIS PRODUCT
19 AND ENROLLING THREE ADULTS TO SEE IF THEY EXPERIENCE
20 ANY ADVERSE EVENTS. SO IT REALLY IS FOCUSED ON
21 SAFETY.

22 DR. STEWARD: THANK YOU. I SEE LARRY HAS
23 A HAND UP.

24 DR. GOLDSTEIN: YES. SO I WANT TO GIVE A
25 PARTIAL RESPONSE TO ANNE-MARIE'S QUESTION ABOUT

BETH C. DRAIN, CA CSR NO. 7152

1 PERHAPS AN OUT-SIZE INVESTMENT RELATIVE TO THE
2 FREQUENCY OF THE DISEASE. AND I'LL JUST POINT OUT
3 FOR ANNE-MARIE AND FOR THE PUBLIC WHO MAY NOT BE
4 WELL INFORMED ON THIS POINT, THE MEDICAL COMMUNITY
5 OFTEN DEVELOPS THERAPIES FOR RARE DISEASES. AND
6 PART OF THE REASON FOR THAT IS THAT THEY OFTEN
7 PROVIDE A GOOD TECHNOLOGY PLATFORM THAT CAN THEN BE
8 BROADENED OUT TO MORE COMMON DISEASES IN THE PUBLIC
9 AT LARGE.

10 SICKLE CELL IS A PARTICULARLY GOOD TARGET
11 IN THAT CONTEXT BECAUSE IT'S A WELL-DEFINED DISEASE
12 GENETICALLY. THERE ARE A VARIETY OF TECHNOLOGY
13 PLATFORM APPROACHES THAT ARE BEING TESTED FOR THIS
14 TYPE OF DISORDER, AND I THINK WE'LL SEE THAT ONE OF
15 THEM MAY EVENTUALLY BECOME THE STANDARD, NOT JUST
16 FOR SICKLE CELL DISEASE, BUT FOR MORE COMMON
17 DISORDERS THAT ARE PERHAPS LESS WELL DEFINED IN THE
18 GENERAL CATEGORY OF COMMON DISEASE.

19 DR. STEWARD: THANK YOU, LARRY. OTHER
20 COMMENTS FROM BOARD MEMBERS? I DON'T SEE ANYTHING.
21 MARIA, DO YOU HAVE ANY HANDS UP?

22 MS. BONNEVILLE: NOPE.

23 DR. STEWARD: OKAY. THEN COMMENTS FROM
24 THE PUBLIC.

25 MS. BONNEVILLE: THERE ARE NO COMMENTS

BETH C. DRAIN, CA CSR NO. 7152

1 FROM THE PUBLIC THAT I SEE.

2 DR. STEWARD: OKAY. TERRIFIC. THEN WE'LL
3 PASS IT TO YOU, MARIA, FOR CALL OF ROLL.

4 MS. BONNEVILLE: DAN BERNAL.

5 MR. BERNAL: YEA.

6 MS. BONNEVILLE: ANNE-MARIE DULIEGE.

7 DR. DULIEGE: YES.

8 MS. BONNEVILLE: MARK FISCHER-COLBRIE.

9 DR. FISCHER-COLBRIE: YES.

10 MS. BONNEVILLE: FRED FISHER.

11 DR. FISHER: YEA.

12 MS. BONNEVILLE: DAVID HIGGINS.

13 DR. HIGGINS: YEA. YIPPEE. GOOD.

14 WONDERFUL.

15 MS. BONNEVILLE: STEVE JUELSGAARD.

16 MR. JUELSGAARD: YES.

17 MS. BONNEVILLE: DAVE MARTIN. ADRIANA

18 PADILLA.

19 DR. PADILLA: YES.

20 MS. BONNEVILLE: JOE PANETTA.

21 MR. PANETTA: YES.

22 MS. BONNEVILLE: AL ROWLETT.

23 MR. ROWLETT: YES.

24 MS. BONNEVILLE: OS STEWARD.

25 DR. STEWARD: AS MY LAST OFFICIAL VOTE ON

BETH C. DRAIN, CA CSR NO. 7152

1 THE ICOC, I CANNOT FAIL TO FOLLOW MARIA'S
2 INSTRUCTIONS AND SAY YEA.

3 MS. BONNEVILLE: JONATHAN THOMAS.

4 CHAIRMAN THOMAS: YES.

5 MS. BONNEVILLE: MOTION CARRIES.

6 CHAIRMAN THOMAS: OKAY. WELL, THANK YOU,
7 MARIA. THANK YOU, OS.

8 I HAD ONE COMMENT IF I MIGHT. I WAS
9 REMISS IN FORGETTING TO SAY SOMETHING IN THE CONTEXT
10 OF OUR BRIDGES DISCUSSION, WHICH IS JUST THIS LAST
11 WEEK WE HAD A FANTASTIC ANNUAL BRIDGES CONFERENCE
12 THAT WAS PUT TOGETHER AND EXPERTLY DESIGNED BY DR.
13 KELLY SHEPARD. AND I WANTED TO GIVE KELLY A
14 SHOUT-OUT. THE CONFERENCE, AS ALWAYS, WAS A GREAT
15 COMBINATION OF PI TALKS, OF STUDENT POSTERS, WHICH I
16 MIGHT ADD, WHEN THINGS GET BACK TO NORMAL, WHENEVER
17 THAT IS, I WOULD STRONGLY RECOMMEND TO ALL OF YOU
18 THE ANNUAL CONFERENCE THAT BRIDGES HOLDS IN JULY, TO
19 TRY TO GO TO THAT CONFERENCE TO SEE THESE POSTERS,
20 TO HEAR THE PROJECTS THAT THE STUDENTS HAVE PUT
21 TOGETHER. IT'S SO IMPRESSIVE. ALSO A GREAT PANEL
22 WITH PATIENT ADVOCATES AS WELL AS BRIDGES ALUMNI.
23 JUST ALL IN ALL A TERRIFIC TWO-DAY EVENT.

24 SO, KELLY, THANK YOU VERY MUCH FOR YOUR
25 HARD WORK IN RUNNING THAT AS WELL AS OUR OTHER

BETH C. DRAIN, CA CSR NO. 7152

1 EDUCATIONAL PROGRAMS.

2 BEFORE I GET TO MY VERY LAST COMMENT, I
3 MUST GIVE CREDIT WHERE CREDIT IS DUE. THIS IS
4 DIRECTED TO MR. JUELSGAARD, MR. ROWLETT, THAT WE'VE
5 GOT -- THE GIANTS TOOK THE FIRST OF SEVEN GAMES OF
6 THE NEXT TEN DAYS FROM THE DODGERS LAST NIGHT. I'M
7 NOT HAPPY, BUT BEING A STAND-UP GUY, WANTED TO
8 CONGRATULATE YOU ON THAT, AND WE WILL SEE WHERE THAT
9 GOES FROM HERE.

10 MY FINAL COMMENT, IN CASE YOU WERE
11 WONDERING --

12 MR. ROWLETT: YEA.

13 CHAIRMAN THOMAS: THAT WASN'T CALLING FOR
14 A VOTE, AL. THANK YOU.

15 IF YOU'RE WONDERING WHAT OS JUST
16 MENTIONED, SO THIS IS SORT OF A HAPPY BUT
17 BITTERSWEET ANNOUNCEMENT AT THE SAME TIME. SO ALL
18 OF US ON THE BOARD KNOW WE HAVE TERM LIMITS. OS HAS
19 BEEN ONE OF OUR ORIGINAL BOARD MEMBERS FROM
20 INCEPTION AND HAS BEEN INVALUABLE IN THE EXTREME IN
21 MANY DIFFERENT CAPACITIES. HIS TIME ON THE BOARD IS
22 OFFICIALLY UP. THE GOVERNOR YESTERDAY OR COUPLE
23 DAYS AGO FORMALLY SENT A LETTER TO MARIA NOMINATING
24 HIS SUCCESSOR, WHO IS RICH LAHARLA, WHOM WE WILL
25 INTRODUCE TO YOU AT A FUTURE MEETING TO HEAR ABOUT

BETH C. DRAIN, CA CSR NO. 7152

1 HIS AMAZING STORY. BUT FOR THE MEANTIME AND HAVING
2 HIS APPOINTMENT MADE, THAT MEANS THAT OS' TENURE ON
3 THE ICOC IS COMING TO AN END SHORTLY.

4 AT OUR LARGER MEETING IN OCTOBER, WE WILL
5 PROPERLY FETE AND ACKNOWLEDGE ALL OF OS' MAJOR
6 CONTRIBUTIONS, BUT I JUST WANTED TO LET EVERYBODY
7 KNOW THAT THAT IS WHERE WE ARE. AND SO RATHER THAN
8 GET INTO WHAT WOULD BE A VERY LENGTHY, EMBARRASSING
9 SESSION FOR OS HERE IMPROMPTU, WE WILL HOLD THAT
10 TILL OCTOBER. AND JUST TO SAY AS A SUMMARY
11 STATEMENT, OS, THERE'S NO WAY TO REPAY YOU FOR ALL
12 THAT YOU'VE DONE FOR CIRM, FOR THE PATIENTS OF
13 CALIFORNIA, FOR THE VOTERS OF CALIFORNIA WHO ENABLED
14 THIS GREAT, GRAND EXPERIMENT THAT IS CIRM. AND WE
15 WILL PROPERLY TAKE THAT UP AND SEE YOU IN OCTOBER.

16 MR. TORRES: MR. CHAIRMAN.

17 DR. STEWARD: I WILL RESERVE ANY COMMENTS,
18 WHICH, BY THE WAY, WILL ALSO EMBARRASS SOME PEOPLE
19 ON THIS CALL. WHY IS MARIA LAUGHING?

20 CHAIRMAN THOMAS: I HOPE YOU EMBARRASS
21 MARIA.

22 MR. TORRES: OH, NO. MR. CHAIRMAN, I JUST
23 WANT TO ADD WHAT A CHALLENGE IT WAS TO FIND SOMEONE
24 WHO COULD REPLACE, NOT THAT HE CAN BE REPLACED, OS
25 ON THIS BOARD. I'LL RESERVE MY COMMENTS FOR THE

BETH C. DRAIN, CA CSR NO. 7152

1 LATER FETE THAT WE WILL HONOR HIM AT, BUT I JUST
2 WANT TO SAY INITIALLY THAT, AND WILL LATER AS WELL,
3 THAT I REALLY HAVE ENJOYED MY RELATIONSHIP WITH OS.
4 HE HAS THE BEST RECOMMENDATIONS FOR MEXICAN
5 RESTAURANTS IN IRVINE AND LAGUNA. AND IN ADDITION
6 TO THAT, HE'S JUST A TREMENDOUSLY COMMITTED
7 PROFESSIONAL. BUT I KNOW HE'S PROUD IN THE FACT
8 THAT THE PERSON WHO WILL REPLACE HIM WAS OUR FIRST
9 RECIPIENT OF A STEM CELL TRANSPLANT FOR A SPINAL
10 CORD INJURY. SO IT'S GOING TO BE AN INTERESTING
11 CHANGE, BUT NOBODY CAN REPLACE MY BUDDY OS.

12 DR. STEWARD: THANK YOU, ART, VERY MUCH.
13 MUCH APPRECIATED. AND AS I SAID, MUCH MORE TO BE
14 SAID IN OCTOBER.

15 DR. DULIEGE: OS, I WOULD ONLY SAY THAT I
16 CAN'T WAIT FOR THE SESSION WHERE WE WILL EMBARRASS
17 EACH OTHER, BUT NO MATTER WHAT, WE ALREADY MISS YOU.

18 DR. STEWARD: THANK YOU.

19 CHAIRMAN THOMAS: OKAY. SO WE WILL
20 WITHHOLD ALL FURTHER COMMENT ON THAT SUBJECT TILL
21 OCTOBER.

22 MARIA, WHEN IS THE NEXT MEETING OF THE
23 APPLICATION REVIEW SUBCOMMITTEE?

24 MS. BONNEVILLE: IT'S IN AUGUST, I BELIEVE
25 THE 24TH FROM 10 TO 12.

BETH C. DRAIN, CA CSR NO. 7152

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

CHAIRMAN THOMAS: OKAY. GREAT. WELL,
THANK YOU, GUYS, FOR A VERY PRODUCTIVE SESSION AS
ALWAYS. AND WITH THAT, WE STAND ADJOURNED.

(THE MEETING WAS THEN CONCLUDED.)

REPORTER'S CERTIFICATE

I, BETH C. DRAIN, A CERTIFIED SHORTHAND REPORTER IN AND FOR THE STATE OF CALIFORNIA, HEREBY CERTIFY THAT THE FOREGOING TRANSCRIPT OF THE PROCEEDINGS BEFORE THE APPLICATION REVIEW SUBCOMMITTEE OF THE CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE IN THE MATTER OF ITS REGULAR MEETING HELD ON JULY 20, 2021, WAS HELD AS HEREIN APPEARS AND THAT THIS IS THE ORIGINAL TRANSCRIPT THEREOF AND THAT THE STATEMENTS THAT APPEAR IN THIS TRANSCRIPT WERE REPORTED STENOGRAPHICALLY BY ME AND TRANSCRIBED BY ME. I ALSO CERTIFY THAT THIS TRANSCRIPT IS A TRUE AND ACCURATE RECORD OF THE PROCEEDING.

BETH C. DRAIN, CA CSR 7152
133 HENNA COURT
SANDPOINT, IDAHO
(208) 290-3543